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ABSTRACT 
 
The use of the alpha particle emitting radionuclide 211At for clinical therapy of 
primary and metastatic tumors via targeted methods is an attractive modality for increasing 
cancer management and survivability. While the potential for therapeutic use is great, 
widespread commercial production capability of 211At is currently very limited. 
Development of targetry and distillation apparatus utilizing commercially available and/or 
easily adaptable technology is of paramount importance in developing and maintaining 
the preclinical and clinical availability of 211At. Previous preliminary studies have proven 
the feasibility of 211At production at the Texas A&M Cyclotron Institute utilizing the 209Bi 
(α, 2n) 211At reaction. The goal of this research is to further develop routine 211At 
production equipment and methods to facilitate ongoing in vitro, in vivo, and preclinical 
research. 
Drawing from previous research, an inclined external solid target was developed 
capable of undergoing extended (8+ h) irradiations of 29-MeV (7.25 MeV u-1) alpha 
particles at currents up to 7 μAe. A dry distillation apparatus and process were developed 
to recover the astatine while negating radiochemical contamination from target byproduct 
materials. Several production irradiations were performed with favorable results. 
Production yields ranged between 10.73 – 39.17 MBq µAp-1 h-1 (0.290 – 1.058 mCi µAp-
1 h-1), consistent with published yields, at average beam intensities on the order of 5-10 
times that used in previous experiments (2-3 µAp). Recovered yields were on the order of 
740 MBq (20 mCi) per production run after initial development (median 22.09 mCi ± 
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0.77). No contamination by 210At or 210Po was detected in any of the experiments 
performed.  
Overall, production utilizing these methods has proven feasible for small-scale 
studies utilizing 1-20 mCi per experiment. Development of further process automation 
and miniaturization, as well as quality assurance and current good manufacturing process 
(cGMP) protocols, will be required for forthcoming standardized production. Proposed 
improvements and protocols are provided for future work. 
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NOMENCLATURE 
AuNP Gold nanoparticle(s) 
cGMP Current good manufacturing practices 
CRPC Castration-resistant prostate cancer 
DSB Double strand break(s) 
FDA United States Food and Drug Administration 
FWHM Full width at half maximum 
EOB End of bombardment 
HNSCC Head and neck squamous cell carcinoma 
IRBRB Interdisciplinary radioisotope production and radiochemistry program 
ISO International organization for standardization 
LET Linear energy transfer 
mAb Monoclonal antibody(ies) 
μAe Electrical microampere 
μAp Particle microampere 
RBE Relative biological effectiveness 
RCP Radionuclidic purity 
RCY Radiochemical yield 
TRT Targeted radionuclide therapy 
USP United States pharmacopeia 
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1. INTRODUCTION 
 
The use of the alpha-particle-emitting radionuclides for clinical therapy of primary 
tumors and metastatic disease via targeted methods is an attractive modality for increasing 
the therapeutic effectiveness of cancer treatments. One of the most promising of these 
radionuclides for the development of targeted therapy is 211At. Primary advantages of this 
radionuclide are the clinically useful physical half-life of 7.214 h, as well as the low range 
in tissue and high linear energy transfer (LET) of its alpha particle emissions. These 
characteristics lead to high cytotoxicity, independent of physiological or metabolic oxygen 
levels, lack of dose rate effects, and reduced or negligible dose to non-targeted tissues. 
The resulting high relative biological effectiveness (RBE), coupled with well-known 
halogen chemistry, lends 211At to immunoconjugation and targeted delivery utilizing 
monoclonal antibodies or novel colloidal nanoparticle techniques. While the potential for 
therapeutic use is great, widespread production of alpha-particle emitting radionuclides is 
currently very limited. To increase the availability of this radionuclide, design and 
implementation of targetry and distillation equipment must be completed at the few 
facilities capable of producing 211At in sufficient quantities for on-going preclinical and 
clinical research. 
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1.1 Molecular Radiotherapy of Primary and Disseminated Disease 
 
Molecular radiotherapy or targeted radionuclide therapy (TRT) using 
immunoconjugation, small molecule drugs, and nanoparticle delivery strategies, are 
attractive modalities for the treatment of cancer. These modalities enable the delivery of 
therapeutic levels of radiation to diseased tissue while leaving healthy tissue relatively 
unharmed (Williams et al. 2008, Ting et al. 2009, Ting et al. 2010). Radionuclides utilized 
for TRT are conjugated to biologically active molecules, such as peptides or monoclonal 
antibodies, or molecules with specific organ uptake, such as colloidal nanoparticles. 
Targeting molecules preferentially bind to cancer cells by targeting tumor-specific 
antigens or other over-expressed cell surface receptors (Chattopadhyay et al. 2010, Yang 
et al. 2011). In general, TRT strategies have focused on the attachment of one or more 
radioactive nuclei to a single targeting molecule (Williams et al. 2008). The recent 
utilization of nanomaterials has made it possible to attach several radioactive nuclei to 
multiple targeting molecules, potentially increasing target specificity and therapeutic 
efficacy (Panchapakesan and Wickstrom 2007, Ting et al. 2009, Jokerst et al. 2011, 
Nduom et al. 2012). Based on their unique targeting properties, in addition to treating solid 
tumors, these molecules may find value in treating disseminated and systemic disease. 
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1.2 Alpha-Particle-Emitting Radionuclides Used in Molecular Radiotherapy  
 
The development of molecular radiotherapy or TRT drugs utilizing alpha-particle-
emitting radionuclides is particularly desirable due to increased efficacy of cell killing of 
alpha particles when compared to beta particles (Dadachova 2010, Dashko et al. 2010). 
The majority of United States Food and Drug Administration (FDA) approved TRT drugs 
utilize the beta emitters 90Y and 131I (Williams et al. 2008, Ersahin et al. 2011). However, 
the recent acceptance of the drug Xofigo® (223RaCl2), utilizing the alpha emitter 223Ra for 
the treatment of castration-resistant prostate cancer (CRPC) bony metastases, has shown 
the usefulness of alpha emitters in TRT (Cheetham and Petrylak 2012).  
Alpha particles are generally emitted with energies ranging from 4-6 MeV, as 
opposed to beta particles, which are emitted with lower maximum energies, on the order 
of 1-2 MeV. In addition, alpha particles have a maximum range in tissue of approximately 
150 µm. The resulting high linear energy transfer (LET) leads to a high density of energy 
deposition near the particle track, increasing the probability of inactivating critical cell 
components. This increase leads to a much higher relative biological effectiveness (RBE) 
and probability of cell death than that obtained with beta-emitting radionuclides or 
conventional external beam radiotherapy. It is estimated that less than 20% of energy from 
131I and less than 2% from 90Y is deposited in tumors of 200 μm diameter. The remaining 
energy is deposited in surrounding healthy tissue. (Chen et al. 2012). Put another way, 
95% of beta energy is deposited within 0.992 mm by 131I, and in 5.94 mm by 90Y (Hopkins 
et al. 1998, Zalutsky 2004). 
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Conversely, the range of typical alpha particles is comparable to the dimension of 
most eukaryotic cell clusters (10-50 µm). Coupled with common alpha-particle ranges, 
80-100% of the kinetic energy is deposited within few cells. Therefore, healthy tissue cells 
surrounding a solid tumor volume may be spared, as the alpha particle and most secondary 
electrons are incapable of reaching these cells. From a practical standpoint, alpha-particle 
emitters may be able to sterilize cells via self-irradiation, whereas achieving the same level 
of cellular effects with beta emitters leads to toxicity effects due to total drug concentration 
in the body (Sgouros et al. 2010).  
 
 
1.2.1 Advantages of Astatine-211 
 
Among the many known alpha emitters, only a handful are suitable for use in 
targeted therapies, including 211At, 212Bi, 213Bi, 223Ra, 225Ac, and 227Th (Guerard et al. 
2013). The radionuclide 211At is an ideal candidate for alpha emitter TRT strategies due 
to its relatively short half-life and desirable decay chain, as shown in Table 1 (Zalutsky et 
al. 1989, Guerard et al. 2013). Both 211At and its daughter 211Po (branching ratio of 0.582) 
decay by alpha emission (Lambrecht and Mirzadeh 1985). In addition, several x-rays are 
emitted during decay, which allow potential in vivo imaging and accurate estimation of 
internal dose distributions (Zalutsky and Pruszynski 2011). Compared to the other 
radionuclides shown, 211At has the most clinically useful half-life. Half-lives shorter than 
a few hours prove difficult to manufacture, transport, and administer before significant 
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decay has occurred. Unlike routinely produced radionuclides with short half-lives used in 
positron emission tomography, the processing and labeling procedures for therapeutic 
drugs have not been automatized to the same degree. Half-lives longer than a day or two 
introduce issues with specific activity, labeling efficiency, and committed doses. At first, 
the significant energy yield of alpha particles associated with the heavier radionuclides 
would seem beneficial. However, due to the multiple decays involved, it is likely that 
daughters will have dissociated from the targeting molecule and been transported away 
from the tumor site, such that further emissions are ineffective (Palm et al. 2004, Guerard 
et al. 2013). This is especially true when targeting micro-metastases and cell clusters 
(Aurlien et al. 2000).  
 
Table 1. Common alpha-particle-emitting radionuclides suitable for molecular 
radiotherapy and their physical characteristics. Energy yield includes contributions from 
daughters. Radium, actinium, and thorium have multiple alpha-emitting daughters 
(Zalutsky et al. 1989, Guerard et al. 2013). 
Radionuclide Half-life α Energy × Yield 
(MeV Bq-1 s-1) 
211At 7.214 h 6.92 
212Bi 60.55 m 7.92 
213Bi 45.61 m 5.85 
223Ra 11.43 d 19.93 
225Ac 10.0 d 25.15 
227Th 18.68 d 25.79 
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 Astatine-211 is produced via the 209Bi (α, 2n) 211At reaction. Production of the 
impurity radionuclide 210At competes with this reaction via the 209Bi (α, 3n) 210At reaction 
(Hermanne et al. 2005, Schultz et al. 2006). The impurity radionuclide 210At decays 
primarily to the radionuclide 210Po.  The decay schemes of 211At and 210At are illustrated 
in Fig. 1.  
 
 
Figure 1. The decay schemes of 211At and 210At. The radionuclide 210At is unsuitable for 
molecular radiotherapy because of the long half-life of 210Po. 
 
The deposition and retention properties of 210Po, coupled with the high 
radiotoxicity of this radionuclide, dictate that even trace amounts of 210At impurity present 
in a sample of 211At will make the product unfit for pre-clinical use (Schultz et al. 2006, 
Scott 2007, Ansoborlo et al. 2012). To minimize production of 210At, the nominal incident 
alpha particle beam energy must be maintained below the 28.6 MeV threshold, where the 
cross-section for 210At production is minimal while 211At production cross-section remains 
substantial (cf. Fig. 2) (Lambrecht and Mirzadeh 1985, Hermanne et al. 2005, Martin et 
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al. 2014). The theoretical lower threshold for 211At production is 20.72 MeV (Morzenti et 
al. 2008). 
 
 
Figure 2. Excitation functions for the most probable reactions are shown for 4He nuclei 
incident on 209Bi. Cross sections were extracted from JANIS, using data from Kelly 
1949, Ramler et al. 1959, Lambrecht et al. 1984, Patel et al. 1992, Hermanne et al. 2004, 
and TENDL 2009 (JANIS 2016). 
 
 
 
1.2.2 In-Vitro, In-Vivo, and Pre-Clinical Use of Astatine-211 
 
There have been many studies geared towards the preclinical use of 211At, mostly 
focusing on immunoconjugation for radioimmunotherapy. Initial studies incorporating in 
vitro research have been translated into in vivo use; a few of these studies have progressed 
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to pre-clinical trials stage. An overview of the most widely received of these studies is 
provided below.  
Early in vitro studies have shown survival fractions of 0.37 (D0) occurring with 
one to two nuclear crossings by alpha particles, when conjugated to mAb’s targeting 
human glioma and melanoma cells (Larsen et al. 1998). Similarly, successful results were 
shown with anti-HER2/anti-CD340 labeled astatine in effective therapy of the breast 
cancer cell lines SKBr-3, BT-474, and MCF7 (Akabani et al. 2006). Relative biological 
effectiveness of the trastuzumab (anti-HER2/anti-CD340) labeled astatine showed a 
relative biological effectiveness on the order of ten times higher than external photon 
irradiation.  
As an alternative to immunoconjugation, one study looked at the effectiveness of 
5-[211At]Astato-2’-deoxyuridine for incorporation into DNA. Treatment of Chinese 
hamster V79 lung fibroblasts showed impressive results; untargeted cells were killed by 
neighboring cells, and the incidence of double-strand-breaks (DSB) was approximately an 
order of magnitude higher than what was found for an 125I labeled homolog. Other groups 
have reported similar findings regarding the incidence of DSB (Lyckesvard et al. 2014). 
Dosimetry analysis concluded that D0 levels were reached with 1.2-1.5 decays per cell. 
DNA incorporation greatly increased the effectiveness and reduced the dependence on 
nuclear crossing when compared to cell-surface-receptor targeted moieties (Vaidyanathan 
et al. 1996). Other groups have shown that alpha radiation from 211At results in 
approximately three times as many DSB as compared to low LET radiation (Claesson et 
al. 2007). 
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A similar study was undertaken to compare the efficacy of 211At radiation to more 
common methods in creating aberrations in thyrocytes. Due to a chemical similarity to 
iodine, free astatine naturally accumulates in thyroid tissue. This study showed that alpha-
particle radiation was more effective in causing damage to stationary and cycling cells 
when compared to gamma rays from 60Co. This result could lead to 211At use in the 
treatment of benign thyroid diseases in children with less risk of inducing cancer risks 
over the long term (Lyckesvard et al. 2014). 
More recently, colloidal gold nanoparticles (AuNP) have been investigated for 
targeted delivery of radionuclides, specifically 198Au and 125I (Kannam et al. 2006, Paciotti 
et al. 2006, Hamoui 2015). The most interesting research has focused on size control for 
organ-specific uptake, coupled with mAb or peptide labeling for therapy of 
micrometastases (Chattopadhyay et al. 2010, Kim et al. 2011, Martin and Akabani 
unpublished data 2012, Hamoui 2015). Due to the chemical similarity of iodine and 
astatine, this has been investigated as a method for delivering 211At, as well as in mixed 
radionuclide theranostic use (Bartczak and Kanaras 2011, Martin and Akabani 
unpublished data 2012). 
Pre-clinical and clinical trials have utilized both locoregional administration as 
well as systemic intravenously injected drugs. Locoregional administration has the benefit 
of quick delivery to the tumor cells; de-astatination of delivery proteins, as well as short 
biological half-lives of some targeting proteins themselves, may limit effectiveness in 
some moieties unless locally administered. On the other hand, intravenous injection is 
crucial for treatment of disseminated cancers, including micrometastases and cell clusters. 
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Anti-CD25 mAb 7G7/B6-labelled astatine was studies as a systemically administered 
therapeutic agent for leukemia in mice. Favorable results of 70% survival in 
approximately one and a half months were found, as compared to total population death 
in the control group in the same amount of time (Zhang et al. 2006a). Further studies 
investigated the use of this drug in combination therapy with daclizumab, an anti-Tac 
mAb. This has shown equally favorable results when compared to radionuclide therapy 
by itself, of 91% survival at three months versus 32% survival for the radionuclide alone. 
(Zhang et al. 2006b). The same group also studied 211At-HeFi-1, an anti-CD30 mAb, for 
treatment of leukemia in mice, showing similar survival fractions for combined therapy 
utilizing daclizumab (Zhang et al. 2007). 
A similar methodology was used to investigate 211At-U36, an astatinated mAb 
which targets antigens widely expressed by squamous cell epithelium and squamous cell 
carcinomas originating in the neck, head, esophagus, cervix, and epidermis (Schrijvers et 
al. 1993). This study was used to evaluate treatment of head and neck squamous cell 
carcinoma (HNSCC) in mice via intravenous injection. There was a reduction of tumor 
volume in comparison with controls (Cheng et al. 2007). Systemic administration of 
radioastatine conjugated to smaller proteins, such as the antibody fragment C6.5, targeting 
HER2 receptors, has also been studied (Robinson et al. 2008). 
 Loco-regional administration has been studied extensively in the use of the mAb 
MX35-F(ab’)2 labelled 211At in the therapy of ovarian cancers (Andersson et al. 2000, 
2003, 2009; Back et al. 2005, 2009; Elgqvist et al. 2006a, 2006b, 2006c, 2010; Frost et al. 
2013, Gustaffson et al. 2012). This is important, as the several studies presented below 
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have led to Phase I clinical trials (Guerard et al. 2013). These studies have focused on 
211At-MX35 in the treatment of NIH:OVCAR-3 ovarian cancer cells in murine models. 
The antibody is effective in other forms of ovarian cancer, as it targets the Ley antigen 
expressed in the majority of human epithelial ovarian cancers. These groups have studied 
the effects of tumor size, total administered activity, and fractionation. In general, the 
astatinated MX35 was found to be more effective in treating smaller tumors, supporting 
its use in the targeting of microclusters and disseminated disease. For fractionation, little 
difference was found when splitting doses (maximum of 800 kBq or ~22 μCi) between 
three equal administrations every four days versus a single dose. However, further studies 
showed weekly injections of 400 kBq (~11 μCi) per injection showed a significant 
increase in efficacy when administered three to six times (Elgqvist et al. 2010). The phase-
I clinical trials of 211At-MX35 were investigated as an adjunctive therapy for failed cases 
of phase-III trials. These trials were centered on HMFG1 labeled 90Y for post-surgical 
treatment of ovarian cancer, which failed in some cases due to the inadequacy of beta-
emissions in treating disseminated disease; as such, the alpha-emitting 211At-MX35 
proved to be a very promising option, although results are still pending (Guerard et al. 
2013).  
 Another series of studies based on intravenous administration of 211At-81C6 
antibodies is equally important and was also taken to phase-I clinical trials (Zalutsky et al. 
1994, 1997). The monoclonal antibody 81C6 targets tenascin, an antigen over-presented 
by gliomas, and has been actively studied in the treatment of apoptosis-resistant brain and 
central nervous system tumors (Blasberg et al. 1987, Zalutsky 2004, Azad et al. 2015, 
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Pozzi and Zalutsky 2017). Phase-I clinical trials used the chimeric form of the antibody to 
reduce possible immunogenicity effect, and focused on the treatment of residual disease 
following surgery, resulting in a statistically significant increase in median survival 
without significant short or long-term neurological side effects to date (Zalutsky et al. 
2008). 
 Several other pre-clinical studies have been started. A large effort has been put 
forth investigating transcriptional response of mice tumors and dose rate effects and 
dependence in vivo. (Rudqvist et al. 2012, 2015). An additional study by this group has 
investigated response in healthy tissue following administration of 211At. This in vivo 
model assessed transcriptional response in BALB/c nude mice and is a step forward in 
assessing long-term toxicity effects and side effects to normal tissue during therapy 
(Langen et al. 2015). More recently, a similar study has investigated the use of compounds 
targeting overexpressed sigma receptors in DU-145 cells (human prostate cancer) in mice 
with both 131I and 211At with good results (Ogawa et al. 2015) 
 
 
1.2.3 Present-day Availability 
 
Despite the attractiveness of 211At for clinical therapeutic use, there are several 
hurdles that must be overcome prior to its adoption as a clinical radiopharmaceutical. 
Current production of 211At is limited to a handful of cyclotrons around the world. 
Furthermore, a recent survey of available cyclotron facilities suggests that there are very 
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few cyclotrons capable of producing 211At at levels needed for use in pre-clinical and 
clinical research (Zalutsky and Pruszynski 2011). The Texas A&M University Cyclotron 
Institute and Interdisciplinary Radioisotope Production and Radiochemistry Program 
(IRPRP) is one of the few facilities capable of producing 211At at high yields; therefore, 
establishing routine production of 211At will be a significant step towards overcoming this 
deficiency. In addition to limited production sources, further development of advanced 
radiochemical techniques for efficient isolation of 211At is needed to minimize loss and 
maintain repeatability during post-production processing (Lindegren et al. 2001, Zalutsky 
et al. 2001, Zalutsky and Pruszynski 2011). Finally, a better understanding of chemical 
properties, in vitro and in vivo studies of uptake and retention profiles, as well as extensive 
pre-clinical trials are required for successful demonstration of the use of 211At in TRT 
radiopharmaceuticals (Zalutsky et al. 1989, Kennel et al. 2002, Nakamae et al. 2009, 
Zalutsky and Pruszynski 2011) 
 
 
1.3 Purpose of This Research 
 
This report describes a routine production study of 211At at the Texas A&M 
University Cyclotron Institute as part of the efforts of the IRPRP. The IRPRP’s mission 
centers upon the production of radionuclides for use in diagnostic and therapeutic nuclear 
medicine and radiobiology research, with a primary focus on the development of novel, 
targeted radionuclide strategies. As the first step of establishing this program for targeted 
 14 
 
radionuclide development, preliminary experiments were previously conducted at the 
Texas A&M Cyclotron Institute to establish the production of 211At (Bhakta 2011, Martin 
and Akabani 2012, Martin et al. 2014). These initial experiments guided the next step 
towards routine production, the experiments and results of which are presented in this 
dissertation. 
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2. MATERIALS AND METHODS 
 
 
2.1 Properties of Astatine-211 
 
The radionuclide 211At has a unique set of characteristics which make it suitable 
for use in targeted therapy. The physical properties of 211At, such as half-life and double 
alpha-particle-emission combine well with biological effects of its emissions to effectively 
kill cancer cells. 
 
 
2.1.1 Physical Properties 
 
The radionuclide 211At is an ideal candidate for therapeutic modalities due to its 
relatively short half-life of 7.214 h and emissions (Zalutsky et al. 1989). This half-life 
provides a reasonably high emission rate, while still being long enough to allow efficient 
tumor uptake and retention. Astatine-211 decays by electron capture to 211Po (branching 
ratio = 0.582), which in turn decays by alpha particle emission. Alternatively, 211At decays 
by alpha particle emission to 207Bi, followed by electron capture. The decay scheme of 
211At and the impurity 210At are shown in Figure 1. While 211Po is available in the 
metastable state as 211mPo from other production methods, it is not fed by 211At decay due 
to high nuclear spin and associated low decay probability (Groppi et al. 2005). 
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In addition to the double alpha emission, several x-rays are emitted during decay, 
which allow for in vivo imaging and accurate estimation of internal dose distributions 
(Lambrecht and Mirzadeh 1985, Zalutsky and Pruszynski 2011). The most common 
emissions and energies are provided in Table 2 (National Nuclear Data Center 2016). 
More complete decay information is provided in Appendix A. 
 
 
Table 2. The most probable decay emissions and energies are provided for 211At, 210At, 
and pertinent decay products (National Nuclear Data Center 2016). Decay modes with 
negligible yields are disregarded. 
Radionuclide Emission Energy (MeV) Yield (Bq-1 s-1) 
211At α 5.870 4.18×10-1 
211Po α 7.450 9.89×10-1 
211Po α 6.892 5.46×10-3 
211Po α 6.658 5.37×10-3 
210At α 5.1 – 5.5 Less Than 10-3 
210Po α 5.304 1.0 
    
Radionuclide Emission Energy (keV) Yield (Bq-1 s-1) 
211At γ 687.0 2.61×10-3 
211Po γ 569.7 5.35×10-3 
211Po γ 897.8 5.51×10-3 
211At Kα 1 79.29 2.11×10-1 
211At Kα 2 76.86 1.27×10-1 
207Bi Kα 1 74.97 3.65×10-1 
207Bi Kα 2 72.80 2.17×10-1 
211Po Various x-rays 74 – 85  Less Than 10-4 
210At γ 245.3 7.95×10-1 
210At γ 1181.4 9.93×10-1 
210At γ 1436.7 2.90×10-1 
210At γ 1483.4 4.65×10-1 
210At γ 1599.5 1.34×10-1 
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 In addition to the useful emissions, which will be discussed further under 
biological effects, 211At has interesting and useful chemical properties. As a halogen, 
astatine functions as a homolog to iodine. Radioactive iodine isotopes, including 123I, 124I, 
125I, and 131I, are widely used in diagnostic imaging via SPECT and PET, in therapy as 
sodium or potassium 131I, and a wide variety of investigational and nuclear medicine 
techniques utilizing radiolabeled compounds. Free astatine accumulates in thyroid and 
stomach, similarly to iodine (Lyckesvard et al. 2014, Watanabe et al. 2016). The common 
use of radioiodine and these similarities make it a good candidate as a homolog for 
investigating astatine behavior both chemically and biologically. Despite the similarities, 
there are several significant differences (Appelman 1960, Aaij et al. 1975). 
 In general, astatine is less tightly bound that iodine in similar compounds, due to 
the size of the atom. This leads to the stability of carbon-halogen bonds to be weaker for 
astatine than corresponding iodine compounds (Wunderlich et al. 1989, Talanov et al. 
2004, Ogawa et al. 2015). There are several consequences. First, more stable bonding 
structures may need to be used in vivo to prevent premature dissociation of the astatine 
and the targeting moiety.  This premature dissolution requires the use of more complex 
chelating agents and transport molecules than are commonly used with iodine, such as tin 
based trimethylstannyl-benzamide immunoconjugates (Anaheim et al. 2015a, 2015b), tin 
based precursors to octreotide labels (Vaidyanathan et al. 2006, 2007b), rhodium based 
complexes (Rajerison et al. 2014), succinimidyl-astatobenzoate (Hadley et al. 1991) and 
other complex molecules (Friedman et al. 1977, Pruszynski 2015). In addition, astatine is 
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more easily volatilized than iodine, which, when coupled with its lower chemical stability, 
makes inhalation a concern during radiochemistry procedures. 
Moreover, changes in the oxidation state of astatine in solution occur over time. It 
is generally believed that these changes are due to the formation of oxidative species by 
self-irradiation over time (Pozzi and Zalutsky, 2007). The various ionic states of astatine 
found in water or common elution media add to the difficulty in labeling and other 
processing. Especially during distillation, it is important to avoid the At(0) state, as it is 
easily absorbed on glass, quartz, or metal surfaces when acidity is introduced. Citrate 
buffer is commonly used in elution mixtures to help prevent this tendency. There is some 
argument in the literature regarding the existence of this state versus di-astatine (At2) 
molecules. (Zona et al. 2008). Table 3 shows the known or expected ionic states of astatine 
(Appelman 1960, Zona et al. 2008). Guerard et al. provide an extensive review of the 
chemical properties of astatine in both inorganic and organic applications (Guerard et al. 
2013).  
 
Table 3. Common ionic states of astatine are presented with a description of each 
(Appelman 1960, Zona et al 2008, Guerard et al. 2013). 
Ionic State Description 
At(-I)           Astatide, anionic form of At- 
At(0)           Neutral astatine, or di-astatine as found in At2 
At(I)           As found in the ipoastatite anion, At(I)O- 
At(III)           As found in astatite, At(III)O2- 
At(V)           As found in the astatate anion, At(V)O3- 
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2.1.2 Radiobiological Effects 
 
The biological effects of the emissions from 211At are fundamental to its use as a 
therapeutic agent. Radiobiology and radiation effectiveness require an understanding of 
energy deposition and transfer mechanisms, linear energy transfer (LET), cellular 
response to radiation damage and radiations of different types, and other considerations. 
At a microscopic level, heavy charged particles, such as alpha particles, interact in 
a wholly different manner than lighter ions, such as electrons or beta particles. While both 
particle types deposit energy directly through electronic interaction, the higher mass of 
alpha particles results in a relatively straight track with a high density of ionization 
surrounding the track. In comparison, beta-particles produce a widely divergent track with 
low density of ionizations. In addition, alpha particles are generally produced with kinetic 
energies on the order of 5-20 times larger than beta particles, resulting in a higher total 
number of ionizations. The total number of ionizations, coupled with the frequency with 
which they occur, play an integral part in the transfer of energy per unit path length as well 
as the probability of creating substantial damage. 
The concept of the density of ionizations per unit path length is commonly given 
in terms of LET. Alpha particles have a higher LET by 2-3 orders of magnitude, resulting 
in much higher cytotoxicity and relative biological effectiveness (Chen et al. 2012, Hauck 
et al. 1998) The higher density of ionizations results in a higher concentration of double-
strand breaks and other densely manifested lesions produced by alpha particles traversing 
the cell nucleus. The result is a much lessened cellular repair ability (Raju et al. 1991, 
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Dadachova 2010, Chen et al. 2012). Figure 3 shows the surviving cell fractions as a 
function of absorbed dose for various radiations (Bhakta 2011). The relative biological 
effectiveness of alpha emitters has been shown to be significantly greater than x-rays in 
all cell cycle stages (Claesson et al. 2011). Double strand breaks induced by 211At have 
been shown to cause a skewed distribution in DNA fragment size, as compared to gamma 
irradiation and associated random fragment size distribution (Danielsson et al. 2013). It is 
not known whether this is one of the contributing factors for increasing RBE of alpha 
particles. (Claesson et al. 2007). 
While assessing cell survival fractions as a function of absorbed dose has been the 
traditional method for assessing relative biological effects, it is more useful to consider 
other methods. The stochastic patterns of energy distribution along alpha tracks can lead 
to a wide variation of cell killing per unit absorbed dose. Attempting to describe these 
effects has led to the more useful measurement of the probability of creating lethal damage 
per particle transversal of the cell. Other models for assessing alpha-induced cellular 
damage include tumor control probability models and microdosimetric techniques 
(Roeske and Stinchcomb 1996, Roeske and Stinchcomb 1999, Roeske and Stinchcomb 
2000, Unak 2003, Sgorous et al. 2010). These models are useful for determining effects 
in treating single cells and small tumor clusters.  
The average number of particle transversal to result in a certain survival fraction 
is very dependent upon source distribution and concentration within the cells, cell cycle 
phase, and cellular geometry (Sgouros et al. 2010). To illustrate the role of geometry, Palm 
et al. noticed a large effect when studying 211At effectiveness. When cell surface bound 
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211At decayed to 211Po, the polonium detached and diffused away from the receptor site 
prior to decay (T1/2 = 0.516 s). The resulting change in solid angle reduced the 
effectiveness when compared to cell surface located decays by a factor of two (Palm et al. 
2004). In other studies, alpha particle track autoradiography has been used to define in 
vivo cellular and intracellular distribution of 211At radioactivity (Brown et al. 1992, Brown 
et al. 1994). 
 
 
Figure 3. A comparison of radiobiological characteristics of various radiations as a 
function of absorbed dose, showing the relatively superior effectiveness of high LET 
radiation, such as alpha particles. Reprinted from Bhakta 2011. 
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 An average of 1.5-3 transversals per cell nucleus is required to reduce survival to 
37% (D0), although the observed range of cellular traversals to achieve this number of 
nuclear traversals is anywhere from 1-20 per cell (Raju et al. 1991, Langen 2015, Rudqvist 
2015). From these measurements, the mean free path between lethal events, λ, is derived, 
with an equally wide range of values, from 1.5-64.4 μm (Sgouros et al. 2010). Targeting 
methods that introduce astatine into the nucleus are even more effective. Astatine-211 
labeled thymidine analogs in V79 lung fibroblasts in Chinese hamsters show better than 
ten times as many DSBs than similar 125I labeled compounds. It is thought that this extreme 
radiotoxicity is related to the destruction of the genome. (Walicka et al. 1998). 
In addition to studies on the effectiveness of 211At, there has been some concern of 
toxicity related to the long-term effects of the daughter radionuclide 207Bi. However, due 
to the long half-life (31.55 y) and smaller branching ratio (0.418), it is expected that long-
term deposition in the bone, kidneys, and liver will be negligible (Guerard et al. 2013). 
Further studies into this issue and long-term radiotoxicity will be required when moving 
forward with FDA approvals.  
 
 
2.1.3 Production Mechanisms 
 
Nuclear reactions involving energetic charged particles are governed, to a large 
extent, by the kinetic energy of the incident particle and the composition of the target 
medium. At low incident energies, coulombic repulsion and energetic effects limit nuclear 
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interactions, resulting in scattering. As incident kinetic energy increased, it becomes 
possible for the charged particle to overcome this coulomb barrier. In many cases, a 
smaller energy than what is suggested by the coulomb barrier is permissible due to 
quantum tunneling (IAEA 2009a). Interactions of interest, such as the production of 211At, 
are inherently endothermic by nature. Thus, the incident particle must also have sufficient 
energy to overcome this mass and binding energy difference, known as the Q-value. 
Excitation functions, or energy-dependent cross-sections, have been experimentally 
determined for many particles and energies incident on a variety of targets (Lambrecht 
and Mirzadeh 1985, IAEA 2009a, IAEA 2009b). These experimental results, as well as 
computational estimations from codes such as TALYS, have been compiled in a freely 
available database by the Organisation for Economic Cooperation and Development 
(OECD) and the Nuclear Energy Agency (NEA) (Koning 2008, JANIS 2016).  
Astatine-211 is primarily produced via the 209Bi(α, 2n)211At reaction. While other 
reaction mechanisms are available, such as 209Bi(7Li, 5n)211Rn 211At and 
234Th(p, cx)211Rn211At, these are not commonly used due to low yields and/or low 
availability of machines capable of using these methods (Maeda et al. 2015). The common 
helium on bismuth production method has become the most widely studied, due to the 
availability of machines capable of producing this reaction, ease and cost of obtaining 
materials, and control of contaminants. 
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2.2 Cyclotron Production of Astatine-211 
 
  The clear majority of 211At is produced by the (α, 2n) reaction. This necessitates 
the availability of 20-28 MeV alpha particles at fluence rates of a large enough magnitude 
to produce useful quantities of the radionuclide (Henriksen et al. 2001). Practically 
speaking, this requires cyclotrons dedicated to the acceleration of alpha beams. The large 
number of biomedical cyclotron facilities in use have machines designed for proton and 
deuteron beams, optimized to produce positron-emitting radionuclides (IAEA 2009a). 
While there are dedicated biomedical cyclotrons available of newer manufacture capable 
of accelerating alpha particles, for example, the IBA Cyclone series, they have not yet 
been widely commissioned (Zalutsky and Pruszynski 2011). These cyclotrons are the most 
desirable for their high current capability when compared to large research cyclotrons 
intended for physics research. Large cyclotrons are optimised for high currents for heavier 
particles at higher energies, with a correspondingly low current available at the 
comparatively low energies necessary for 211At production, as can bee seen from Eq. 1: 
 
        (1) 
 
where Q is the beam intensity in μAp, k is a machine-dependent constant, v is a machine-
dependent constant (typically v ≈ 1.5) and E is the particle energy in MeV (Kim et al. 
2014). A similar equation, given maximum energy as a function of bending factor, K, is 
shown as: 
vkEQ =
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        (2) 
 
where E is the particle energy in MeV, K is the bending factor, z is the electric charge of 
the accelerated ion in Coulombs, and M is the mass of the accelerated ion in amu. Some 
smaller research cyclotrons have been adapted to radionuclide production use. For 
example, a Scanditronix MC-50 adapted to this purpose can produce alpha particles with 
energies of 27 MeV and beam intensities of up to 70 μAe (Balkin et al. 2013). These are 
impressive yields, capable of producing activities greater than 19 mCi of 211At in 45 
minute at EOB. 
 The Texas A&M Cyclotron Institute is a large interdisciplinary research facility 
housing two cyclotrons. The K-150 88” cyclotron, a near copy of the unit at Lawrence 
Berkeley National Laboratory, was commissioned in 1967 and utilizes a new electron-
cyclotron-resonance (ECR) ion source to produce positive ions. Using alpha particles in 
the +2 charge state, the expected maximum particle energy and intensity are 45 MeV u-1, 
and 10 μAp. This is assuming a bending factor of K = 140, and a maximum transmission 
of 25%. Using Eq. 1, the estimated maximum beam current at 28 MeV (7 MeV u-1) is 
approximately 5 μAe, considering machine variations.  The K-500 cyclotron was 
constructed in the early 1980’s and is primarily geared towards high energy physics 
experiments and production of rare beams. It utilizes an ECR source, but is not capable of 
producing large currents in the energy range necessary for direct bombardment of bismuth 
for astatine production (Laune et al 1983a, Laune et al. 1983b, Youngblood 1990, 
1−= KzME
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Youngblood 1991). A schematic drawing of the Texas A&M University Cyclotron 
Institute is given in Fig. 4. The beamline with the astatine production target location is 
notated. 
 
 
 
Figure 4. The Texas A&M University Cyclotron Institute facility layout. The astatine 
production target location is next to the large bending magnet near the K-150 cyclotron. 
Reprinted from Bhakta 2011. 
 
 
 Preliminary experiments and proof-of-concept irradiations were carried out using 
the K-500 cyclotron, as the K-150 was undergoing extensive restorative maintenance over 
a time frame of several years. Briefly, 80 MeV (20 MeV u-1) helium atoms were extracted 
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and bombarded a set of aluminum and copper degradation foils before impinging on a 
bismuth target. These degradation foil packs were designed to reduce the beam energy to 
nominally 25.5 MeV (6.38 MeV u-1) and 27.8 MeV (6.95 MeV u-1), while allowing for 
higher currents than would have been available at endpoint energies. Still, currents on 
target were in the range of 0.10-0.15 μAp. These experiments showed nominal yields on 
the order of those found in the literature and gave valuable experience in target design and 
materials handling (Martin et al. 2014). This was applied to the target development and 
utilization of the K-150 described in this research. 
 
 
2.2.1 Targetry 
 
Astatine-211 is produced by the (α, 2n) reaction on natural bismuth. In most cases, 
targetry consists of bismuth melted or plated onto an aluminum target backing plate 
(Birattari et al. 2004). Both internal and external targets have been used to varying degrees 
of success (Martin et al. 2014). Published yields and target descriptions comparing 
previous results are given in Table 4. As can be seen from these data, incident beam energy 
and target thicknesses are carefully controlled. These constraints are imposed by the 
excitation functions and particle interactions, as described in the following subsection. 
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Table 4. Reported yields of 211At are shown from various sources at end of 
bombardment. Sources marked with an asterisk indicated an internal target was used. 
Source Incident Energy (MeV) 
Target 
Thickness 
(μm) 
211At Yield EOB 
(MBq μAp-1 h-1) 
Martin et al. 2014 27.8 500 36.0 
Martin et al. 2014 25.5 500 12.4 
Wunderlich et al. 1986 28 20 4 
Lambrecht & Mirzadeh 1985 28 100 5.3-10.4 
Aaij et al. 1975 33 500 7.4-14.8 
Rosch et al. 1985 28 500 8.56 
Larsen et al. 1993 28 250 8-12 
Hadley et al. 1991 28 500-800 10-12 
Larsen et al. 1995 28 100 15.2-15.6 
Hamwi et al. 1991 28 30 27.7 
Groppi et al. 2005 28.8 - 31.9 
Lebeda et al. 2005* 29.5 3-5 38 
Larsen et al. 1996* 28 50 41 
Schwarz et al. 1998* 28-29 30-80 37-41 
Schwarz et al. 1998 27.3 1000 10.6 
Alfarano et al. 2006 28 250 48 
 
 
In general, the clear majority of targets designed to produce 211At have consisted 
of bismuth attached to an aluminum backing plate. Bismuth is ideal in that natural bismuth 
(100% natural abundance) can be used without the added expense and complication of 
isotopic enrichment.  
 Sample excitation functions were shown in Fig. 2, and are presented below in Fig. 
5. The (α, 2n) cross section becomes negligible below energies of 18-20 MeV. An upper 
threshold of 28.6 MeV (7.15 MeV u-1) is set to eliminate production of the impurity 
210At/210Po, generated by the (α, 3n) reaction. As can be seen, careful control of incident 
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energy and target thickness is required to maintain the desired reactions, while minimizing 
contamination from unwanted interactions and maintaining target integrity. 
  
 
 
Figure 5. Excitation functions are shown for 210At and 211At production (Bhakta 2011). 
 
 
The collision stopping power, dE/dX, or differential energy loss rate per distance, 
of a heavy ion interacting in matter, can be given by 
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where dE/dX is the collision stopping power in MeV cm-1, ρ is the target material density 
in g cm-3, Z is the target material atomic number, A is the target material atomic mass in 
amu, z is the charge of the projectile, I is the mean excitation potential, and β is the 
relativistic projectile velocity, which is in turn given by 
 
 
 (4) 
 
where M0c2 is the rest mass of the projectile. The mean excitation potential, I, is 
experimentally determined and depends solely upon the target material. Radiative 
stopping power is disregarded, as it is negligible in the energy range of interest for heavy 
charged particles (Attix 2004). 
 Using Eqs. (3) and (4), the continuous slowing down approximation range can be 
estimated using 
 
  
     (5) 
 
where Ei is the initial projectile energy in MeV, Ef is the final projectile energy in MeV, 
and R is the range, in cm. The continuous slowing down approximation range is only 
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approximate, as it does not take into account energy straggling and range straggling (Attix 
2004). 
 The above equations can be used to determine the range of 28 MeV alpha particles 
incident upon natural bismuth. Taken to an endpoint of no residual kinetic energy (Ef ≈ 0 
MeV), the range is approximately 180-200 μm. However, taken to an endpoint of Ef = 19 
MeV, the range is approximately 30-50 μm. These estimations are consistent with more 
rigorous computation using the code SRIM (Stopping and Range of Ions in Matter), as 
well as previously reported results (Lambrecht and Mirzadeh 1985, Ziegler et al. 2010). 
An example of ten thousand simulated 28 MeV alpha particles incident on bismuth is 
shown in Fig. 6. This is a graphical output from SRIM, showing straggling and lateral 
projections, which showcase the stochastic nature of radiation transport. Median range 
was computed to be 202 μm, with a straggling factor of 6.5 μm, and an average lateral 
dispersion of approximately 10 μm. 
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Figure 6. Particle track depth (ranges) is shown for ten thousand 28 MeV alpha particles 
incident on bismuth. 
 
 
Projectile range as a function of energy has considerable impact on target design, 
given the energy deposition characteristics of heavy charged particles. These particles 
deposit energy with the typical Bragg peak, where the vast majority of the particle energy 
is deposited near the end of the particle track. For example, using 28 MeV alpha particles 
in bismuth, 14 MeV is deposited in approximately the last 65 μm, and 7 MeV in the last 
25 μm. To illustrate this, stopping power for 30 MeV alpha particles incident on bismuth 
are shown versus energy in Fig. 7, and versus depth in Fig. 8. Data for these plots were 
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generated using SRIM. Because of this Bragg distribution, there is a decidedly non-
uniform distribution of heat flux in the target volume. 
 
 
Figure 7. Stopping power for alpha particles incident on bismuth is shown as a function 
of energy. 
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Figure 8. Stopping power for 30 MeV alpha particles is shown as a function depth in 
bismuth. 
 
 
Some of the biggest obstacles in efficient target design for 211At production are 
thermal considerations. The low melting point (272 °C) and the low thermal conductivity 
(7.86 W m-1 K-1) of metallic bismuth limit the amount of heat flux that can be applied to 
a target without negative consequences, such as melting and loss of designed target 
geometry by deformation. For example, as ductile metals approach the melting point, the 
force exerted by their own mass can cause bending and deformation, affecting target 
geometry. Three main factors influence the thermal qualities of a target: characteristics of 
the incident heat flux, physical characteristics of the target, and heat removal qualities. 
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Incident heat flux is primarily driven by the incident beam characteristics. Focal 
spot size, beam energy, and beam intensity are the main considerations. As seen in Fig. 7, 
the fundamental physics involved in heavy charged particle transport results in non-
uniform heat deposition as a function of depth in the target. Due to the physics involved 
both with cyclotron motion and beam steering, energy and intensity distributions are non-
uniform in lateral and radial directions. Changes in focal spot size and shape can greatly 
affect these distributions, and localized “hot spots” are possible. When possible, after 
beam tuning, radiographic film is exposed in the location of the target holder to analyze 
these beam characteristics. However, in these experiments, the lack of a dedicated vacuum 
isolation valve made this impractical. It is imperative that all target regions remain below 
336.8 °C, the boiling point of astatine, with a considerable safety factor. In practical terms, 
preventing liquefaction of the bismuth target will both preserve target geometry and 
provide adequate margin against localized hot spots which could cause evaporation of 
produced astatine (Martin et al. 2014). 
One method of controlling thermal characteristics while maintaining higher 
current is to use an internal target. Several groups have experimented with this method 
(Larsen et al. 1996, Schwarz et al. 1998, Lebeda et al. 2005). The creation of a curved or 
angled target placed in the beam line within the cyclotron at a grazing angle allows the 
beam to spread out over a large area, thereby reducing incident heat flux. These targets 
have generally shown higher yields, at shorter run times, which makes them attractive for 
routine production. However, there are several possible drawbacks. First, any excessive 
or localized heating may cause contamination of the cyclotron. This is of minimal concern 
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during operation, as any off-gassed material will likely be captured in the cryopumps, and 
cyclotron internal components are already highly radioactive. However, during 
maintenance, and especially ion source replacement, effluent concentrations of astatine 
can become high (Hull and Roberson 2011). More importantly, maintaining vacuum with 
an easily removable target system can pose some difficulties. Reusable targets, made to 
the high tolerances required, are prone to damage during the distillation process. 
Disposable targets must be made to fairly high tolerance standards, which increases their 
cost. The end benefit of increased beam on target can negate these downsides; for example, 
beam currents of approximately 65 μAe have been reported, as opposed to 15 μAe for 
external targets (Zalutsky and Pruszynski 2011). Graphite leading edge and trailing edge 
monitors may be used on internal targets to provide some indication of beam distribution. 
(Larsen et al. 1996, Zalutsky and Pruszynski 2011). 
Other groups have experimented with vertical beam irradiation of bismuth shot 
contained within a sealed aluminum capsule. This method reduces temperature 
considerations, as any volatilized astatine due to the melting of bismuth is contained within 
the capsule. Volatilized astatine is transferred back to a liquid or solid state following 
irradiation, but prior to dry distillation (Nagatsu et al. 2014). 
Utilizing the stopping power equation and the nonlinear energy deposition with 
depth brings to light one of the most attractive methods for reducing heat deposition in the 
bismuth target. By utilizing an extremely thin layer of target material, a maximum of only 
8-9 MeV may be deposited per particle. For example, calculations using SRIM showed 
that an approximately 30 μm layer of bismuth would reduce incident alpha energy from 
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28 MeV to 19.5 MeV. This energy range encompasses the useful cross section range of 
the (α, 2n) reaction, and allows the majority of the beam energy to be deposited in a more 
robust backing material, such as aluminum. The main difficulty lies in target 
manufacturing. Target foils of bismuth are not readily available in thicknesses of less than 
150 μm. Machining an aluminum target backing plate with a slot to press or melt bismuth 
into is a standard practice; however, 30 μm corresponds to approximately 0.0012”, which 
is close to the tolerance limit of most standard milling machines. Additionally, melting or 
pressing bismuth target material results in non-uniform target thickness, especially on the 
front face of the target. These complications leave electroplating or vapor deposition, 
which have not been thoroughly investigated, in part due to complexity and difficulty in 
setting up a system for small scale production (Larsen et al. 1996, Lindegren et al. 2001, 
Yordanov et al. 2004). The problem of target thickness is exacerbated when the target is 
angled. For example, a 30 μm target angled at 80° normal to the incident beam gives a 
perceived thickness of 173 μm. To create a 30 μm path length under these conditions 
would require a thickness of only 5.2 μm. 
Preliminary 211At production experiments at the Texas A&M University Cyclotron 
Institute utilized a 500 μm thick bismuth target normal to the incident beam, and did not 
utilize active cooling. However, beam intensities on-target were low, in the range of 0.096-
0.163 μAp, with an approximate incident heat flux of 13 W cm-2 (Martin et al. 2014). 
Copper and aluminum degradation foils, with high thermal conductivities (401 W m-1 K-1 
and 237 W m-1 K-1, respectively), coupled with the substantial aluminum target body, 
aided in heat dissipation. 
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Routine production experiments utilizing the K-150 cyclotron have an expected 
maximum incident heat flux of 375 W cm-2, assuming a circular beam diameter of 10 mm 
and a uniformly distributed beam current of 5 μAp on a thick target. Therefore, more robust 
cooling methods are required. Several solutions have been incorporated into the routine 
production target. First, the target has been oriented at an angle of 80° normal to the 
incident beam. This orientation results in a reduction of incident heat flux to approximately 
65 W cm-2. A maximum of 80 W cm-2 is designed for, to accommodate the Gaussian beam 
radial distribution. Second, cold deionized water, cooled to 4 °C, with an approximate 
flow rate of 1.5 L min-1, may be flowed through a channel milled into the rear of the target 
holder. Third, pyramidal indentations have been implemented into the aluminum target 
backing. This increases the contact surface area between the bismuth and the aluminum, 
increasing conductive heat transfer, while also improving mechanical adhesion between 
the dissimilar materials. Fourth, silicon dioxide thermal grease is available for layering 
between the aluminum target backing and the target holder apparatus. This may increase 
thermal conductivity as well, by removing air gaps between the surfaces. However, this 
may prove problematic during dry distillation. The grease must either be removed 
satisfactorily by chemical means, or the bismuth-astatine matrix must be mechanically 
separated from the target backing while preventing contamination by this thermal grease. 
Finally, a quick-change clamping mechanism was developed to attach the target backing 
plate to the target holder. This was designed to provide a rapid release of the target, as 
well as provide increased pressure between the holder and backing plate to increase 
thermal conductivity. 
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A picture of the production target is provided in Fig. 9. In this figure, the alpha 
beam is incident from the right side and passes through a rectangular collimator slit, visible 
in the picture. The thermocouple for measuring target temperature is seen, as is the fitting 
for coolant water. Not present is the clamping device. Also, note the Teflon insulators on 
the two rods to which the collimator is mounted. This electrical isolation allows for 
monitoring of the incident beam electrical current during irradiation.  
 
 
 
Figure 9. The production target holder is shown. Details of the apparatus are given in the 
text. 
 
 A depiction of the bismuth target and aluminum target backing is provided in Fig. 
10. These show the original target backing, prior to incorporation of the pyramidal 
indentions. The aluminum backing plate measures 9.05 cm (3 9/16”) long by 2.06 cm 
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(13/16”) wide, by 0.32 cm thick (1/8”). Into this plate, a slot is milled that measures 1.27 
cm (1/2”) wide, and 7.62 cm (3”) from end to end (or 2.5” center to center). This slot 
measures approximately 0.5 mm (0.02”) deep. A dimensioned drawing of the target is 
provided in Fig. 11. The result is a thick target, with a bismuth layer of approximately 500 
μm. A target angle of 80° normal to the incident beam resulted in a path length of better 
than 2.8 mm. Pure bismuth beads (99.999%, Sigma-Aldrich) were melted and deposited 
into the target backing plate. During cooling, excess bismuth was scraped from the surface, 
while simultaneously pressing the bismuth into the slot. This process results in some non-
uniformities in target volume (voids, unevenness, etc.), especially on the target surface, as 
seen in the figure. These variations led concerns of thermal conductivity through the 
target/target backing interface. Pyramidal indentations in the target backing slot were 
implemented to assist in this. 
 
 
Figure 10. The basic target backing is shown, bare, and filled with bismuth. 
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Figure 11. A dimensioned drawing of the target is shown. Dimensions are in cm. 
 
 
2.2.2 Thermal Analysis 
 
To determine approximate target thermal characteristics, a simplified thermal 
analysis was necessary. A more rigorous thermal analysis, utilizing computational 
methods, and with more complete characterization of beam parameters, will be necessary 
for future production of commercial targets. A preliminary calculation using a one-
dimensional heat transfer model is provided below (IAEA 2009b, Williamson 2010). 
 Fourier’s Law can be stated in terms of separable first order partial differential 
equations. Taken in a single dimension, this can be stated as 
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 (6) 
 
where jx is the heat flux (W cm-2) in the x direction, k is the thermal conductivity in W cm-
1 K-1, and ∂T/∂x is the partial differential temperature in the x direction. Here, the 
assumptions are made that the x direction is normal to the target surface, heat transfer in 
the orthogonal directions is negligible, and that thermal conductivity remains constant as 
a function of temperature. While it is possible to calculate the heat deposition with depth 
utilizing the stopping power equation, some further simplifying assumptions can be made. 
All energy deposition is assumed to occur at the Bragg peak, or at a beam depth of 
approximately 200 μm. Using the target geometry, this results in a uniform plane 35 μm 
from the front surface of the target. A uniformly distributed, circular beam of 10 mm 
diameter is assumed which results in an ovoid projection measuring 10 mm in width by 
57.6 mm long. Since it is assumed there is no heat transfer in orthogonal directions, and 
heat flux is normalized per unit area, beam size can be neglected. Finally, as the front 
target face is exposed to high vacuum of approximately 5 × 10-6 torr, heat transfer through 
the front surface is negligible. Coupled with the very poor thermal conductivity of 
bismuth, and to simplify initial estimates under steady state conditions, a constant 
temperature throughout the bismuth layer was assumed. A pictorial description of the 
problem is provided in Fig. 12. 
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Figure 12. A pictorial description of the heat transfer problem is presented. 
 
 
 A coupled version of Eq. (6) is derived to describe conduction through the bismuth 
layer as well as the aluminum backing plate: 
 
 
    (7) 
 
where kAl = 2.37 W cm-1 K-1 is the thermal conductivity of aluminum, dAl = 0.27 cm is the 
thickness of the aluminum backing plate, kBi = 0.0786 W cm-1 K-1 is the thermal 
conductivity of metallic bismuth, dBi = 0.0465 cm is the thickness of the bismuth target 
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between the aluminum and the Brag peak, T0 is the maximum temperature, T1 is the 
temperature at the bismuth/aluminum interface, and T2 is the temperature at the 
aluminum/water interface. Using the simplifications given above, the case where T0 = T1, 
which will allow a solution using convective heat transfer equations, was considered. 
 Considering one-dimensional heat transfer via forced convection, the heat flux 
removal is given by Eq. (8) 
 
      (8) 
 
where h is the convective heat transfer coefficient in W cm-2 K-1, and Tw is the bulk 
temperature of the water in the cooling channel. The convective heat transfer coefficient 
is highly dependent upon boundary layer, geometry, fluid properties, surface friction, and 
other contributing factors. Heat transfer also depends upon laminar or turbulent flow, and 
the ratio of convective heat transfer to conduction through the liquid. The Nusselt number 
(Nu) gives an indication of these properties, and is related to h by the equation 
 
       (9) 
 
where Dh = 0.423 cm is the characteristic length in cm, and kw = 0.0058 W cm-1 K-1 is the 
thermal conductivity of water at 20 °C. For flow through a pipe or channel, the 
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characteristic length is equal to the hydraulic diameter, which for a rectangular cross 
section is given by  
 
 
      (10) 
 
where a and b are the channel length and width, in cm. For relatively small differences 
between the bulk water temperature and the interface temperature, and smooth surfaces, 
the Nusselt number can be approximated by the Dittus-Boelter equation, given by 
 
     (11) 
 
where Re is the Reynolds number and Pr is the Prandtl number. These dimensionless 
numbers define viscous and diffusivity effects. In constrained flow, the Reynolds number 
is given by 
 
  
     (12) 
 
where ρw = 0.998 g cm-3 at 20 °C, V = 124.4 cm s-1 is the flow velocity, and μw = 0.0098 
g cm-1 s-1 is the viscosity of water at 20 °C. V is obtained using the known volumetric flow 
rate (1.5 L min-1) and the channel cross sectional area (0.201 cm2). The result is a Reynolds 
number of approximately Re = 5358, which indicates flow is turbulent. 
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 The Prandtl number is given by 
 
     (13) 
 
where Cp,w = 4.186 J g-1 K-1 is the specific heat capacity of water at 20 °C. Solving Eq. 
(13) gives a Prandtl number of Pr = 7.07. Substituting these values of Re and Pr, and 
utilizing Eqs. (9) and (11), solve for a convective heat transfer coefficient of h = 0.663 W 
cm-2 K-1. 
 Using water at 4 °C, the interface temperature can be calculated. Using this 
information, various temperature distributions and incident heat fluxes can be tabulated 
from iterative solving to provide an estimate of maximum beam currents give the 
simplified cooling conditions and a maximum bismuth temperature of 272 °C. These data 
are presented in Table 5, and are only approximate due to the number of assumptions and 
simplifications made. This may be especially true of Eq. (11) due to the large difference 
in temperature between Tw and T2. Using a conservative maximum temperature of 260 °C 
to account for non-uniformities, and to keep localized heating well below the melting point 
of bismuth, the target design should readily handle up to 8 μAp of incident current. 
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Table 5. Temperature ranges are reported for various values of incident heat flux. 
Heat Flux,  j 
(W cm-2) 
Current, Q 
(μAp) 
Tw 
(°C) 
T2 
(°C) 
T0 
(°C) 
165.2 10.3 04 253.2 272 
160.2 10.0 12 253.7 272 
155.3 09.7 20 254.3 272 
163.9 09.2 04 251.3 270 
159.0 08.9 12 251.8 270 
154.1 08.7 20 252.4 270 
160.9 09.1 04 246.7 265 
155.9 08.8 12 247.2 265 
151.0 08.5 20 247.8 265 
157.8 08.9 04 242.0 260 
152.9 08.6 12 242.6 260 
147.9 08.3 20 243.1 260 
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2.2.3 Theoretical Yield 
 
The yield, or activity produced, of a cyclotron-produced radionuclide is an overall 
measure of the target efficiency. Yield is generally given in terms of activity produced per 
incident particle, for instance in units of MBq μAp-1 h-1, or similar. As production and 
decay are dynamic processes, the time of determination of yield must be stated, and is 
customarily taken as the end of bombardment (EOB). Processing and distillation yields 
are usually stated in terms decay corrected back to EOB. 
 Maximum yields depend upon target thickness, composition, and irradiation time. 
Calculations are made easily when considering a so called ‘thick’ target; that is, a target 
in which incident particles are expected to stop, based on Eq. (5). Theoretical thick target 
yields are also calculated for irradiations of a sufficiently long time that the saturation 
factor approaches unity. The saturation factor is given by 
 
      (14) 
 
where λ is the decay constant of the produced radionuclide (λ = ln(2) T1/2-1), and t is the 
irradiation time. Thus, the saturation yield goes to a maximum as the saturation factor goes 
to unity. This limit is approachable as the ratio of irradiation time to half-life increases. 
For example, irradiating for a period equal to t = 3.3 T1/2 gives a saturation factor of greater 
than 90%. This can be achieved for short-lived radionuclides; however, extremely long 
irradiations become impractical for long-lived radionuclides. 
( )teSF λ−−= 1
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 The rate of radionuclide production is given by Eq. (15)   
 
  (15) 
 
where N is the number of radioactive nuclei, Φ is the incident fluence rate in               
particles cm-2 s-1, and σ(E) is the energy-dependent interaction cross section in mb. Note 
the saturation factor imbedded in the equation. This equation makes uses of several 
simplifying assumptions, including a constant and uniformly spatially distributed particle 
fluence rate, negligible burn-up (or activation) of daughter products, negligible decrease 
in target nuclei, and no radioactive or daughter nuclei at t = 0 (Knoll 2000, Attix 2004). 
Incident fluence rate can be calculated using the incident beam current and beam diameter 
by 
 
     (16) 
 
where Q is the beam current in μAp, and a is the beam cross sectional area in cm2. This 
assumes that the beam diameter is smaller or equal to the projected target surface area, as 
well as a uniformly distributed beam in both energy and space. Utilizing equations (15) 
and (16), along with tabulated cross section data, maximum thick target yields can be 
calculated as 
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     (17) 
 
where Y(E) is the energy-dependent thick target yield in MBq μAp-1, and n is the number 
of target nuclei (Lambrecht and Mirzadeh 1985, Basunia et al. 2007). This can easily be 
solved using discretized versions of the stopping power and cross sections through 
reasonably narrow binning through the target. Tabulated cross section data are provided 
in Table 6 (Lambrecht and Mirzadeh 1985, Hermanne et al. 2005). These data are 
plotted in Fig. (13), with a fitted polynomial curve. 
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Table 6. Cross sections for the 209Bi (α, 2n) 211At reaction are tabulated as a function of 
energy. Data without energy error are from Lambrecht and Mirzadeh. 
E Error  σ(E) Error   E Error  σ(E) Error 
(MeV)  (mb)   (MeV)  (mb) 
21.1 2.0  014.0 02.0   25.6 --  561.8 16.9 
21.4 --  012.8 01.0   26.4 --  589.6 17.7 
21.8 1.8  023.0 03.0   26.7 1.2  651.0 65.0 
22.0 --  068.3 02.6   26.8 --  715.2 21.5 
22.2 --  072.2 02.2   27.7 --  761.1 22.8 
22.9 --  164.3 05.0   28.1 --  826.7 24.8 
23.1 1.8  195.0 23.0   28.2 1.2  733.0 73.0 
23.5 1.6  224.0 27.0   28.3 1.0  770.0 77.0 
23.8 --  309.8 19.7   28.4 --  837.7 24.8 
24.0 --  348.8 10.5   29.2 --  906.5 26.9 
24.7 --  432.2 13.0   29.6 1.0  868.0 87.0 
24.8 --  450.5 13.5   29.9 0.9  822.0 82.0 
25.0 1.3  454.0 54.0        
 
 
 
 
 52 
 
 
Figure 13. The fitted excitation function for the 209Bi (α, 2n) 211At reaction is shown. 
 
 
 Using stopping power and range data from SRIM (c.f. Fig. 7), second order 
polynomial equations were fitted to the data between 20 MeV and 30 MeV. In this range, 
stopping power (R2 = 0.9999) and range (R2 = 1) can be estimated by: 
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where dE/dx is in MeV cm-1, R is in cm, and E is in MeV. Using equations (17-19), the 
thick target saturated yield can be calculated for this target. The result is shown in Fig. 14, 
and compares favorably with published yields, as seen in Fig. 15 (Lambrecht and 
Mirzadeh 1985). The actual product yield may be calculated from radiation measurements. 
This is discussed further in section 2.4. 
   
 
 
Figure 14. The thick target saturated yield is shown, as calculated, from 21.1-29.9 MeV. 
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Figure 15. Published thick target yields are shown for comparison with the calculated data 
in Fig. 14. 
 
 
 
The nuclear reaction code TALYS was used to estimate production yields and 
validate the theoretical calculations. In the TALYS code, multiple nuclear models are used 
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to simulate nuclear reactions, and provide complete reaction channel and yield analysis 
for given bombardment parameters (Koning 2008). The relevant input and output decks 
are provided in Appendix B, along with the results. In summary, negligible impurity 
production was expected at energies below 26.8 MeV. Production thick target yields for 
211At were calculated as 16.2 – 23.5 MBq μAp-1 h-1 for 4 h bombardments of 26 MeV 
incident particles, resulting in a thick target saturation yield of approximately 116.6 MBq 
μAp-1 (3.15 mCi μAp-1), comparable to the analytical estimates of 159.5 MBq μAp-1 (4.31 
mCi μAp-1). The yield calculated using TALYS falls in the middle of the range reported 
in the literature (c.f. Table 4), and is approximately 25% lower than the analytical solution 
at 26 MeV. 
 
 
2.3 Recovery Methods 
 
There are various recovery methods used to separate 211At from the target bismuth 
material and other impurities. Most researchers utilize dry distillation, while some have 
investigated wet chemistry recovery methods. Here, chemical methods will be briefly 
discussed, followed by an in-depth analysis of the dry distillation methods used in these 
sets of experiments. 
Few groups have pursued the route of wet chemistry recovery methods as a 
feasible method for routine distillation of 211At. However, from an automation and routine 
production standpoint, wet extraction methods may be more consistently reproducible, 
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and are certainly easier to scale to production capabilities (Balkin et al. 2003; Yordanov 
et al. 2004). Liquid methods would also be more easily implemented in standard-sized 
module enclosures utilized in existing facilities. The insulation and component size needed 
for dry distillation methods dictate a reasonably large volume to incorporate the furnace 
and cold trap in well-shielded hot cells or chemistry module enclosures. The reduction in 
needed space adds to the attractiveness of liquid recovery methods. 
One seldom used method of 211At production is via decay of 211Rn. Maeda et al. 
pursued this route as a generator system, however little further development has occurred. 
This lack of interest is primarily due to several logistic details, as well as the relatively 
exotic production method, consisting of 60 MeV 7Li particles incident on a natural lead 
and bismuth targets to produce both bismuth, and astatine directly, via the                  
209Bi(7Li, 5n)211Rn and natPb(7Li, xn)209-211At reactions (Maeda et al. 2015). Considerable 
chemistry and radionuclidic purity issues are present with this method. 
More practically, papers by Balkin, Bourgeois, and Zona have explored wet 
extraction of astatine produced by the standard (α, 2n) reaction (Bourgeois et al. 2008, 
Zona et al. 2008, Balkin et al. 2013). Balkin focused on wet chemistry methods dissolving 
the irradiated bismuth target in concentrated nitric acid. The acid was removed by 
distillation at relatively low temperatures to prevent volatilization of astatine, and the 
residue was re-dissolved in hydrochloric acid. The 211At was extracted from this solution 
into di-isopropyl-ether (DIPE), and thence back extracted from DIPE into sodium 
hydroxide. Extraction yields resulted in 71-78% efficiencies over many experiments 
(n=55). However, the difficulty arises in the various ionic states of the recovered astatine. 
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HPLC analysis showed significant variations in astatide, astatate, and other species, and 
occasional inclusion of trace impurity metals, which complicated further labeling steps. 
Zona et al. pursued a very similar procedure to Balkin, with yield claims in the 90-97% 
range. However, the various astatine ionic states remained a problem (Zona et al. 2008). 
Bourgeois et al. pursued a wet chemistry recovery method, however they differed 
in extracting the astatine by binding it to a stannylated active ester (N-
hydroxysuccinimide-meta-trimethylstannylbenzoate ester, MeSTB) and extracting it with 
DIPE in the presence of N-chlorosuccinimide (NCS). This proved beneficial in further 
immunoconjugation techniques, as so called NHS/EDC coupling chemistry is a widely-
used method (Fischer 2010). In this technique, N-hydroxysuccinimide (NHS, which forms 
the base of MeSTB), is used with (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride) (EDC) and several buffers to link proteins, such as monoclonal antibodies, 
to other molecules (Lewis et al. 2001, Fischer 2010, Bartczak and Kanaras 2011). The 
procedures used by Bourgeois resulted in 85% recovered yields, with 20-25% labeling 
yields. This method showed promise for radiopharmaceuticals based on tin precursors, but 
may prove difficult for other delivery molecules. A similar method by Rajerison produced 
rhodium complexed radioastatine and radioiodine following extraction utilizing 
hydrochloric acid and DIPE back extraction. Again, this showed decent recovery 
efficiencies, but with limited end-use capabilities (Rajerison et al. 2014). 
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2.3.1 Dry Distillation 
 
 Dry distillation makes use of the relatively low boiling point of astatine (336.8 °C), 
by heating the target and extracting the gaseous product. In most applications, this consists 
of a quartz crucible that contains the target within a miniature tube furnace. The crucible 
is sealed, apart from a flow of inert gas which is used to entrain volatilized astatine and 
carry it to another location for capture. The gas flow is normally extracted through 
microcapillary tubing. There are two primary methods of astatine recovery following 
volatilization. In the cold trap method, the outlet capillary is coiled and immersed in a cold 
bath, such as a mixture of methanol or ethanol and dry ice. The cold trap, at -70 to -80 C, 
causes the astatine to solidify and remain in the capillary. Various eluents are then used to 
extract the astatine from the capillary tubing (Friedman et al. 1977, Larsen et al. 1996, 
Lindegren et al. 2001, Zalutsky et al. 2001). In the direct recovery method, the volatilized 
astatine is bubbled through chilled chloroform, which captures the astatine directly 
(Zalutsky et al. 2001). Either method is suitable for conjugation to tin-based 
immunoconjugates or other labeling modalities (Aneheim et al 2015b, 2015c, 2015d). 
 The basic procedure is to introduce the irradiated bismuth and aluminum target 
into the room temperature, or lightly preheated, furnace, on a quartz plate or crucible. 
Quartz can withstand significantly higher temperatures than required for the distillation, 
and will contain the liquefied aluminum and bismuth mixture. If practical, it is beneficial 
to remove the bismuth/astatine layer from the aluminum target backing to reduce the 
distillation time, as well as remove an additional source of contaminants. Once sealed, the 
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furnace is heated, and a flow of dry argon or nitrogen is used to purge the crucible volume 
during the heating. Once the operational temperature range is reached, the gas flow will 
entrain the gaseous astatine and remove it from the crucible. Gas is passed at a volumetric 
flow rate in the range of 15-50 mL min-1 (Aneheim et al. 2015a). The experimental 
configuration used in these experiments is shown in Fig. 16. 
A nominal temperature profile for the furnace and target as a function of time is 
provided in Fig. 17. This shows the initial furnace temperature profile and phase change 
temperatures of the elements involved. Also shown is the approximate target temperature 
as a function of time. In preliminary studies, the target temperature was recorded using a 
blank target sample and an infrared thermometer through the quartz tubing, so 
temperatures are only approximate. The nominal temperature profile shown is developed 
based upon furnace capabilities, as well as empirical measurements from the literature 
(Hadley et al. 1991, Lindegren et al. 2001). A summary of representative distillation yields 
from the literature is given in Table 7. 
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Figure 16. The distillation setup is shown. Argon is flowed through the regulator on the 
right (A), through the quartz tube (B) located within the tube furnace (C), and then 
through the capillary on the left into the cold trap (D). The cold trap is monitored for 
temperature (E) and is located in the shielded dose calibrator well (F), which allows for 
online monitoring of radioactivity (qualitative only). 
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Figure 17. The temperature of the furnace and target during the distillation procedure 
are shown as a function of time. 
 
 
 
 
Table 7. Dry distillation yields are shown as a function of distillation temperature as 
summarized from the literature (Hadley et al. 1991). The sources used somewhat arbitrary 
temperature binning. Recovered yields varied wildly. 
Furnace Temperature (°C) Recovered Yield (%) 
600 29 
600-625 44 
600-650 21, 58, 18 
625-675 19 
650-675 30 
650-700 75, 52, 45, 20 
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Using the dry distillation method, gaseous distillate activity concentration as a 
function of time and flow rate can be approximated by 
 
     (20) 
 
where C(t) is the activity in the still at time t, C0 is the initial activity, k is an experimental 
constant, F is the average argon volumetric flow rate, V is the still volume, and t is the 
time (Nagatsu et al. 2014). The assumptions are that distillation starts immediately at time 
t = 0, that temperature is constant at some value above the boiling point of astatine, and 
that there are no losses or secondary trapping effects. However, this approach is overly 
simplistic and does not consider several factors, including the time taken to ramp the 
furnace to distillation temperatures, fractional bypassing of the cold trap, and non-
uniformities in target heating and astatine migration or diffusion within the bismuth 
matrix. Importantly, the surface tension of molten bismuth and mobility of astatine 
bubbles may significantly slow this process. 
 
 
2.3.2 Elution 
 
Recovery of the solid phase astatine from the capillary tubing requires flushing 
with a solvent or carrier phase. In this process, the capillary coils are removed from the 
cold trap and allowed to warm to room temperature. A small amount of fluid is then passed 
( )VkFteCtC −= 0)(
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through the capillary, into a recovery vial. Alternatively, the eluent may be passed back 
and forth through the capillary repeatedly, to increase recovered yield. 
Preliminary experiments showed poor elution with ethanol, with much better 
results when sodium citrate solution was used. Others have used methanol to good success 
in a similar process (Ogawa et al. 2015). Methanol mixed with N-iodosuccinimide 
(MeOH/NIS), a mild oxidant, has shown good eluent yields on the order of 90%. This is 
comparable with the effective, but less desirable, elution yields of chloroform (Aneheim 
et al. 2015a). Chloroform was used widely in initial astatine recovery experiments, and 
has been shown to be a good eluent with high recovery yields. This has been especially 
helpful in preclinical trial situations, where the astatine/chloroform solution is stable for 
several hours. However, there are two main drawbacks. First, chloroform tends to be 
“messy” in the laboratory, having a relatively low boiling point, and correspondingly high 
vapor pressure and volatility. Coupled with the volatility of astatine, this can lead to 
contamination of the work area, especially in the preclinical environment. Second, most 
immunoconjugation procedures of interest with astatine are not conducive to use with 
chloroform. In these instances, the chloroform must be evaporated, with the astatine 
dissolved into another carrier (Aneheim et al. 2015a). 
It is desirable to use a minimum amount of eluent to maintain a high specific 
activity. Labeling efficiency and activity concentration are highly dependent upon 
minimizing eluent volume. For example, commercially available radionuclides, such as 
125I, are available in the range of 5-10 mCi per 100 μL. Because of the predominantly low 
beam currents available for astatine production as most facilities, and the resulting low 
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produced activity, it is imperative to use the minimum eluent volume possible. However, 
this is compounded by flushing efficiency. Reports of 20-40% recovery per 500 μL flush 
are common, contrasted with 60-90% recovery for 1 mL to 3 mL flushes (Lindegren et al. 
2001, Nagatsu et al. 2014). One strategy, implemented in these experiments, is to 
repeatedly flush with the original 0.5 mL volume. Other limiting factors are the dead 
volume involved with the coiled capillary cold trap, as well as difficulties in handling such 
small volumes both routinely, and reproducibly. 
 High specific activity is a critical factor in the radiolabeling process, as well as in 
in vivo studies. First, specific activity can greatly affect the required volumes and labeling 
efficiencies during immunoconjugation. This is even more apparent when performing 
colloidal nanoparticle synthesis with incorporated radioactivity, as the distribution of 
radioactive atoms per nanoparticle is entirely dependent upon specific activity (Kannan et 
al. 2006, Paciotti et al. 2006, Chattopadhyay et al. 2010, Kang et al. 2010). Second, 
specific activity, in terms of total administered mass, can affect both in vivo effects of the 
drug by altering cell receptor sensitivity, or by toxicity. These effects are carefully studied 
in preclinical and Phase I clinical trials (Hoffman et al. 2001, Pruszynski et al. 2015). 
 
 
2.3.3 Preparation for End Use 
 
As stated previously, use of automated methods to reduce manual processing in 
synthesis and labeling operations is crucial for adapting 211At to routine production for 
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widespread phase II and phase III clinical trials, as well as commercial uses (Aneheim et 
al. 2105a, 2015d). Contrary to manual labeling methods, future routine production 
chemistry will likely lean towards astatination of active molecules (mAb’s, peptides, 
proteins) after the linking molecule has been conjugated to the biomolecule complex. This 
approach has several advantages. First, having as many steps accomplished prior to 
astatination reduces the lead time between end-of-bombardment and end use. This also 
reduces the amount of time the complex molecules are in the presence of the high specific 
activity alpha radiation, which can lead to radiolysis and degradation of the drug over time 
(Pozzi and Zalutsky 2005a, 2005b, 2007, 2017). Second, studies have shown that 
conjugated biomolecule precursor material can be prepared in advance and stored for long 
periods, provided proper temperature and pH conditions are met (Aneheim et al. 2015c). 
Advance preparation allows components to be shipped and stored similarly to other 
components in common cyclotron produced drugs in current use.  
 Several standard methods are in use for astatination of biomolecules. The most 
widely used method involves the coupling of a stannylated succinimide ester to lysine on 
a mAb of interest. Astatine is then substituted for the Sn(CH3)3 group via an electrophilic 
substitution reaction using N-iodo-succinimide (NIS) (Aneheim et al 2015d). An 
exhaustive analysis of vial and column rinse efficiencies has been compared by the same 
group for various solvents, including 5% NIS solution in methanol, methanol, ethanol, 
acetonitrile, 2-propanol, citrate, 15% methanol diluted in citrate, and 50% methanol 
diluted in citrate. Of these, the reference 5% NIS solution in methanol gave by far the best 
results (Aneheim et al. 2015d). This research has built on the similar methods developed 
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by the earlier users (Aaij et al. 1975, Garg et al. 1990, Foulon et al. 1996, Larsen et al. 
1998c). 
 It is critical during recovery, elution, preparation, and labeling, that all processes 
and steps conform to FDA-mandated current Good Manufacturing Practices (cGMP) and 
United States Pharmacopeia standards, specifically USP 797 guidelines for 
pharmaceutical compounding. Chemical and microbial purity must be maintained at all 
times during the manufacture of drugs intended for human use. While this is not necessary 
for preliminary in vitro studies, it is beneficial to conform to these standards as it allows 
an easy transition into preclinical and clinical trials (Anaheim et al. 2015d). 
 
 
2.4 Product Analysis 
 
 Radioactive and chemical analysis of the recovered astatine and end-product is 
essential for fully characterizing and understanding in vitro and in vivo behavior. 
Radioactive analysis, for determining radiochemical yield (RCY), radionuclidic purity 
(RCP), specific activity, and process efficiency, is carried out using radiation detection 
methods. This may be facilitated by gamma-ray spectroscopy, alpha spectroscopy, or other 
methods. Chemical analysis may be performed by use of electron microscope, high-
performance liquid chromatography (HPLC), or reactions with specific reagents capable 
of detecting impurities (Frier and Hesslewood 1980, Mock et al. 1997, Yu 2006). A focus 
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on radioactive analysis is provided herein, as more than basic chemical analysis is beyond 
the scope of this study. 
 
 
2.4.1 Detector Calibration and Analysis 
 
The industry standard method for analysis of cyclotron produced radionuclides is 
via gamma spectroscopy. While not without some drawbacks, gamma spectroscopy 
provides a relatively quick and well-proven method, that is sensitive to radionuclides 
intended for medical use (Knoll 2000). In all cases, it is preferable to use detectors with 
high energy resolution, such as high purity germanium (HPGe), as opposed to inorganic 
scintillators such as NaI and CsI. The increase in availability and decrease in cost of HPGe 
detectors over the last decade, as well as improvements in cooling methods (e.g., 
mechanically cooled), make it unreasonable to use detectors with inferior energy 
resolution for radiopharmaceutical purity measurements. 
While gamma-ray spectroscopy is the method most commonly used, some groups 
have used alpha spectroscopy to determine 211At and 210At/Po purity (Schultz et al. 2006). 
However, alpha spectroscopy requires extensive preparation of standards and samples 
which are not needed with the accuracy and availability of high-energy-resolution gamma 
spectroscopy. 
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2.4.1.1 Gamma-ray Spectroscopy 
 
Gamma-ray spectroscopy of cyclotron produced 211At is carried out utilizing a 
liquid nitrogen cooled HPGe detector with fixed geometry and shielding. The 
experimental setup consists of a Canberra HPGe detector system (Canberra Industries, 
Inc., 800 Research Parkway, Meriden, CT 06450), utilizing an Inspector 2000 
multichannel analyzer (MCA) and Genie data acquisition software package. Prior to 
analysis, the detector system is calibrated using NIST traceable radionuclide sources 
consisting of 57Co (T1/2 = 271.74 d) and 137Cs (T1/2 = 30.07 y) (RadQual, LLC, P.O. Box 
82, Weare, NH 03281), as well as 152Eu (T1/2 = 13.517 y) (Eckert and Ziegler Isotope 
Products, Inc., 24937 Avenue Tibbitts, Valencia, CA 91355). Alternatively, a combination 
of 133Ba and 137Cs may be used, as their emissions cover most of the energy range of 
interest for these purposes. The useful spectral lines and intensities of these sources, and 
spectral lines related to 211At/211Po, are presented in Table 8 (Turkington 1993, NNDC 
2016).  
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Table 8. Gamma and x-ray spectra and intensities are provided for the calibration sources 
and 211At. 
Energy 
(keV) 
Yield 
(Bq-1 s-1) 
Radionuclide 
 
 
 Energy 
(keV) 
Yield 
(Bq-1 s-1) 
Radionuclide 
 
0014.4 9.16×10-2 57Co   0356.0 6.20×10-1 133Ba 
0076.9 1.27×10-1 211At   0383.8 8.94×10-2 133Ba 
0079.3 2.11×10-1 211At   0569.7 5.35×10-3 211Po 
0081.0 3.29×10-1 133Ba   0661.7 8.51×10-1 137Cs 
0121.8 2.85×10-1 152Eu   0687.0 2.61×10-3 211At 
0122.1 8.56×10-1 57Co   0897.8 5.51×10-3 211Po 
0136.5 1.07×10-1 57Co   0964.1 1.45×10-1 152Eu 
0244.7 7.55×10-2 152Eu   1086.0 1.01×10-1 152Eu 
0276.4 7.16×10-2 133Ba   1112.0 1.37×10-1 152Eu 
0302.9 1.83×10-1 133Ba   1408.0 2.09×10-1 152Eu 
0344.0 2.83×10-2 152Eu      
 
 
Activity measurements are performed by correlating detected characteristic photon 
peaks to the radionuclides found present in the target sample. Calibration must be 
performed using a consistently repeatable geometry, such that solid angle and efficiency 
changes are kept to a minimum. Two counting locations are used in the experimental 
setup. The primary location is centered 200 cm from the detector face, and is partially 
surrounded by lead shielding blocks, with an opening towards the detector. This location 
is used to count bulk samples, such as the entire target, and is separated from the detector 
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by this large distance to reduce dead time to an acceptable level. This is especially 
important for initial target measurement, when short-lived impurities, such as 28Al (T1/2 = 
2.245 min, Eγ = 1779 keV, 100%), are dominant.  A second counting location was 
constructed using low-density polypropylene and was designed to hold a sample vial in a 
vertical position approximately 10 cm from the detector face. This position was used for 
small aliquots of activity. Activity at the end of bombardment, Ai (Bq), for a given 
radionuclide i, was calculated using Eq. (21) 
 
   (21) 
 
where Ni,γ is the number of net counts for photon γ from radionuclide i, λi is the decay 
constant of the radionuclide i (s-1), εγ is the absolute efficiency for photon γ, yi,γ is the 
relative emission intensity of photon γ from radionuclide i, tEOB is the bombardment time 
(s), t1 is the time between EOB and initial counting time (s), and t2 is the elapsed counting 
time. Quantities dependent upon experimental setup, such as εγ, are determined 
experimentally beforehand using NIST calibration sources. Background spectra are 
measured and subtracted from the experimental spectra using automatic algorithms 
contained within the Genie analysis software. Using 133Ba and 137Cs sources, with a 
standard background subtraction, the detector efficiency and energy calibrations may be 
performed. For preliminary purposes, all calibrations are performed at the 2 m counting 
location. 
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The detector efficiency at the 2 m location is shown as a function of gamma energy 
in Fig. 18. The detector energy calibration, showing the relationship between gamma 
energy and MCA channel number, is shown in Fig. 19. This fit a linear relationship very 
well, which was desirable. The proportionality should become nonlinear at low energies 
(approximately below 50 keV), however, this effect should be negligible for detection of 
the photons of interest listed in Table 8. Peak width, in terms of full width at half maximum 
(FWHM), is shown as a function of energy in Fig. 20, in units of keV. FWHM is defined 
as 2.35σ for Gaussian distributions, where σ is the standard deviation in counts. Radiation 
interactions follow a Poisson distribution, which very closely approximates the Gaussian 
distribution for a large number of events, and allows for easy discretization using the 
discrete number of MCA channels available (Knoll 2000). The dimensionless energy 
resolution, ER, is given by Eq. (22) 
 
   (22) 
 
where FWHM and E are in units of keV. Energy resolution is shown as a function of 
energy in Fig. 21, and shows a value of approximately 0.2% at 661.7 keV, which is 
consistent with expected results. 
 
E
FWHMER =
 72 
 
 
Figure 18. Detector efficiency for the 2 m source location. 
 
 
Figure 19. Linearity between photon energy and channel number. 
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Figure 20. Peak width in FWHM is plotted as a function of energy. 
  
 
 
 
Figure 21. Energy resolution, in percent, as a function of energy. 
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spectroscopy. Utilizing activity calculations obtained via Eq. 21, the normalized 
production yield, Y (Bq µA-1 h-1), can be calculated using Eq. (23) 
 
    
 (23) 
 
where the integral over total cumulated cuurent (charge) given the total bombardment time 
in µAp-s. In addition to yield analysis, identification of impurity radionuclides can be 
performed using standard spectroscopic analysis techniques (Groppi et al. 2005). 
Dominant gamma lines of expected impurities, namely 210At and 210Po, are given in Table 
2. Other expected gamma lines include 28Al, which will be present in the aluminum target 
holder and target backing. Secondary neutrons produced by the incident beam undergo 
radiative capture reactions on the natural 27Al. However, the activated aluminum dies off 
quickly, with a half-life on the order of 2 minutes. Residual activity is expected to be 
detected in the initial target assay, however, none should be present in eluted samples 
following distillation. Other low-level background radiation is expected from activated 
cyclotron components elsewhere in the facility, as well as 40K and other naturally 
occurring radionuclides. 
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2.4.1.2 Ion Chamber Measurements 
 
 Dose calibrators are widely used in nuclear medicine as means of efficiently 
measuring and verifying the activity of radiopharmaceuticals prior to patient 
administration. Dose calibrators typically consist of a pressurized ion chamber 
surrounding a well in which a dose vial or syringe can be placed. An example of a typical 
dose calibrator, and the same model used in these experiments (Biodex Atomlab 500, 
Biodex Medical Systems, Inc., 20 Ramsey Road, Shirley NY 11967), is shown in Fig. 22. 
As the detector in use is an ion chamber, air-kerma values are measured, and energy 
discrimination of emissions is not possible. Additionally, geometry dependence can be 
very extensive (Rayburn 2007). Generally, a set of 2-5 calibration sources of various 
radionuclides are used to calibrate the detector and to provide daily quality assurance 
checks. These sources must be NIST traceable for preclinical and clinical use. Calibration 
factors, or so called dial values, are set for these radionuclides. Dial values for other 
radionuclides are preset at the factory, using Monte Carlo simulation, empirical 
determination, or other methods. These values are adjusted based on any differences when 
using the calibration sources. This will consider variations in temperature, voltage, and 
any other effects (Rayburn 2007). 
 76 
 
 
Figure 22. The Biodex Atomlab 500 dose calibrator is shown, with ion chamber 
dimensions (Rayburn 2007, © Biodex 2016). Reprinted from Rayburn 2007. 
 
 
 Sealed dose calibrators are incapable of detecting alpha particles or beta particles 
below 1-1.5 MeV, due to wall thickness. Bremsstrahlung photons from higher energy 
betas can provide some signal, although this is generally very unreliable. The wall 
thickness required to contain the pressurized detector gas also poses additional 
complications for low-energy photons, of approximately 70 keV and below. This energy 
range is in line with the x-rays produced by 211At and 211Po. These complications are 
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exacerbated by the geometry, container, and constitution of the sample being measured, 
due to significant attenuation and cubic dependence upon atomic number (Rayburn 2007). 
 One method of circumventing this difficulty in activity measurements is to 
empirically determine dial values by cross calibration with a different detector, such as an 
HPGe (Siegel et al. 2004, Balkin et al. 2013, Bergeron et al. 2014). As seen in Fig. 18, 
germanium detector efficiency is nonlinear at low energies, and as discussed, energy 
calibration can become difficult at low energies. These nonlinearities, coupled with the 
poor dose calibrator response to low-energy photons, makes it preferable to set dial values 
by using the emitted gamma-rays in the 600-900 keV range, even though the emitted yield 
is much lower. Using a different brand of dose calibrator (Capintec, Inc., Model CRC-
15R), Balkin et al. calculated a dial value of 46 (Balkin et al. 2013). A recent version of 
the AtomLab 500 manual provides a factory dial value for 211At of 61.6 (Biodex 2016). 
This is convenient, as comparison between dial values as a function of radionuclide for 
the different manufacturers has shown little to no correlation (Siegel et al. 2004). 
 Due to uncertainties related to volume of eluent, differences in container medium, 
and the lack of significant literature on the use of dose calibrators with 211At for 
quantitative measurements, the ion chambers will be used for qualitative purposes only. 
Aliquots in standard vials will be measured with the dose calibrator; values will be closely 
examined in conjunction with HPGe measurements to validate the quantitative use of dose 
calibrators for future experiments. The dose calibrator located next to the distillation 
apparatus will be used for qualitative on-line measurement of eluted activity. In Fig. 16, 
location (F), the capillary coil and cold trap are located within the dose calibrator well. 
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Measured activity as a function of time will be used to confirm that distillation has reached 
a practical maximum. Referring to Eq. (20), and the expected temperature profile shown 
in Fig. 17, an expected cold trap activity can be estimated, as shown in Fig. 23.  
 
 
 
Figure 23. Expected cold trap activity, as measured by the dose calibrator, is shown as a 
function of time. 
 
 
In Fig. 23, the rate of release of activity from the target is assumed to vary linearly 
with the temperature difference between the target and the melting point of bismuth, above 
the astatine boiling point threshold. It is expected that the astatine will be more easily 
extracted from the target as the bismuth reaches a higher temperature, allowing a greater 
diffusion rate through the material. The dose calibrator measurements will be used to 
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estimate when the plateau has been reached, approximately between 22 and 24 minutes 
after the beginning of distillation. 
 
 
2.4.2 Radionuclidic Purity and Radiochemical Yield 
 
 The activity of each radionuclide can be measured by the HPGe detector, as 
demonstrated in the above section. While bulk activity measurements are useful in 
determining the initial target activity and the completion of distillation, the activity of each 
individual radionuclide is crucial for determining the radiochemical yield (RCY) and 
radionuclidic purity (RCP). Both quantities are used when determining the quality of a 
radiopharmaceutical product, especially as it applies to the suitability for clinical use 
(Clark 1990). These values also give an indication of the quality assurance and quality 
control procedures provided in a specific process (Decristoforo et al. 2000). 
Radionuclidic purity gives an indication of the amount of impurity radionuclide 
present in a sample. Activity measurement of individual radionuclides is accomplished 
utilizing Eq. (21) and the gamma-ray spectrum of the product after distillation and elution. 
It is conventional to define RCP in terms of activity, although in some early cases it has 
been reported in terms of mass fractions (Smith 1964). Units are generally in terms of μCi 
of impurity per mCi of product, especially when given as limits by USP standards. In 
research, RCP is more commonly given in percentage of total activity. Radionuclidic 
purity can be quoted both prior to labeling, and for the end product. When quoted in 
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manufactured radiopharmaceuticals, the RCP is always quoted in terms of the end-
product. However, in preclinical research, it can be beneficial to measure the RCP through 
various phases of the entire process. 
Radiochemical yield is primarily quoted after the entire processing, labeling, or 
immunoconjugation process is completed. The RCY provides a measure of the efficiency 
of the labeling process, as well as an indication of the end use effectiveness (Eriksson et 
al. 2014). Radiochemical yield can be given by Eq. (24) 
 
 , (24) 
 
where Aproduct is the total activity of the end product, Areaction is the total activity that went 
into the reaction, and RCP is given as the fraction of product radionuclide to total activity 
(Eriksson et al. 2014). This is not decay corrected, but can be done so using the standard 
method. Decay corrected activities are usually stated in terms of EOB activity. 
 
 
2.5 Nanoparticle Formation 
 
Colloidal gold nanoparticles may be formed with the inclusion of radiohalides for 
in vitro studies. Colloidal gold nanoparticles without radioactivity have been extensively 
studied in imaging and drug delivery research (Panchapakesan and Wickstrom 2007, 
reaction
product
A
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Gilijohann et al. 2010). Methods have been largely focused on increasing contrast in 
imaging due to high atomic number and specific organ or tumor uptake via targeted 
labelling (Kang et al. 2010); increased energy absorption to tissue in conventional 
radiotherapy and in laser ablation (Hainfeld et al. 2004, Chattopadhyay et al. 2010); and 
in enhancing quantification in pathology using surface-plasmon resonance and other 
optical properties (Jazayeri et al. 2016). Radioactive gold nanoparticles incorporating 
radioiodine (125I) and 198Au have been developed for internal radiation therapy and 
imaging purposes (Ting et al. 2010, Hamoui 2015, Clanton and Akabani 2016). We 
followed the one-pot modified Turkevich method described by Kumar, with modifications 
developed in the Systems Radiobiology Laboratory (Kumar et al. 2008, Clanton and 
Akabani 2016).  
 
2.5.1 Nanoparticle Synthesis 
 
Colloidal gold nanoparticles may be formed by the Turkevich method. In this 
process, HAuCl4 in solution begins an aggregation process with the addition of a reducing 
agent, traditionally triosodium citrate (Na3C6H5O7 ∙ 2 H2O). In the case of sodium citrate, 
the citrate ions also act as capping agents, protecting the gold colloid and preventing 
further aggregation. Varying the relative concentrations of the reagents, and to some 
extent, the rate of addition of the reducing agent, controls the nanoparticle size (diameter) 
distribution; the reducing agent must be added quickly and consistently between 
experiments to maintain repeatability (Frens 1973). To produce approximately 50 mL of 
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30-40 nm diameter particles, at a concentration of 1011-1012 particles mL-1, the following 
steps are performed: 1) thoroughly wash all glassware with Aqua Regia (3 parts 5 N HCl, 
1 part 6 N HNO3), rinse with doubly-deionized (DI) water, and thoroughly dry; 2) bring 
50 mL of DI water to a boil in a round bottom flask, with a condenser column attached to 
maintain volume; 3) prepare 1 mL of 12.7 mM HAuCl4, and add it to the flask; 4) prepare 
0.94 mL of 38.8 mM sodium citrate solution, and add it quickly to the reaction flask. 
Following addition of the sodium citrate, the reaction will take place over the course of 2-
3 min. Visible changes in the color of the solution provide feedback as to the state of the 
reaction. After 0.5-1 min, the solution will begin to darken, transitioning first to a 
translucent grey and then to a light translucent blue. After 2-3 min, the solution will 
quickly darken to a deep ruby color, indicating completion of the reaction. The solution is 
boiled for a few more minutes to ensure the reaction has gone to completion, before 
removing from the heat. A depiction of the experimental apparatus is shown in Fig. 24. 
Incorporation of radioactive halogens into the nanoparticles was first investigated 
with stable iodine. An equal mixture of sodium iodide (NaI) and sodium hydroxide 
(NaOH) were added to the original sodium citrate solution at 20 mM concentration. The 
reaction was carried out as previously, with no noticeable changes, indicating that the new 
reactants did not negatively affect the reaction. Several trials were carried out using no-
carrier-added 125I in 0.1 M NaOH, as obtained from Perkin-Elmer (940 Winter St., 
Waltham, MA 02451). Added activities ranged from 120 μCi to 2 mCi. Results showed 
nanoparticle formation and size distribution consistent with non-radioactive samples, and 
maintained 87-94% retained activity following washing and labelling procedures. This 
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indicated that most activity was bound to, or incorporated within, the gold nanoparticles. 
Similar results were expected when incorporating 211At into the sodium citrate solution. 
 
 
Figure 24. Experimental apparatus to produce gold nanoparticles: (1) crystallization dish, 
containing silicone oil and stir bar for heat transfer purposes; (2) 100 mL round bottom 
flask (3-neck), containing stir bar and reactants; (3) reflux column; (4) thermometer for 
measuring oil temperature; (5) cold water inlet for reflux column; (6) reflux water outlet; 
(7) hot plate. 
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 As mentioned above, one method of controlling nanoparticle diameter is to vary 
the concentration of sodium citrate added to the reaction. This method is suitable for 
producing nanoparticles in the range of 10-50 nm in diameter. Smaller and larger particles 
may be obtained by utilizing different reducing and/or capping agents, such as sodium 
borohydride (NaBH4) or hydroquinone (C6H4(OH)2) (Jokerst et al. 2011). The 
concentration of sodium citrate was varied from 20 mM to 38.8 mM, while maintaining 
the same volumes. The resulting range of nanoparticle diameters are presented in Fig. 25. 
Here, measurements were conducted for 5 samples of each combination via TEM analysis 
(described below in section 2.5.3). Nanoparticle diameter error was calculated from 
measured quantities, while concentration error was assumed to be 5%. 
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Figure 25. Gold nanoparticle size as a function of peak absorption. 
 
 
 When incorporating radionuclides in the formation process, the average number of 
radioactive nuclei per nanoparticle can be estimated using the Poisson distribution 
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where k represents the number of radioactive nuclei, P(k) represents the probability of 
including k radioactive nuclei in each nanoparticle, and the average, μ, is the total number 
of radioactive atoms divided by the number of nanoparticles. This probability can be 
calculated based on known masses of reactants, added activity, and known nanoparticle 
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size and number density for a given reaction. It is apparent that nanoparticle size, the total 
reaction volume, and activity may be tailored to provide the desired results. As an 
example, 10 mCi of 211At added to a reaction solution for producing 20 nm nanoparticles 
will have a large variation in the number of radioactive atoms per nanoparticle, dependent 
upon the total number of nanoparticles created. This is shown in Fig. 26 for reactions 
scaled to produce 108, 109, and 1010 nanoparticles. 
 
 
Figure 26. The probability of k number of radioactive atoms per nanoparticle is shown as 
a function of the total number of nanoparticles formed for 10 mCi of 211At added to the 
reaction. 
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2.5.2 PEGylation and Labeling 
 
Bare gold nanoparticles are unsuitable for in vitro and in vivo use, as they will 
aggregate in the biological environment, and have negligible circulation or uptake (Ting 
et al. 2010). It is therefore necessary to provide a surface protectant to limit aggregation, 
as well as to provide targeting properties. One method is to provide a biologically inert 
coating of polyethylene glycol (PEG) in a so-called “corona” (Ishii et al. 2004). In this 
case, 2-5 kDa PEG chains, labeled with a thiol group on one end, are put in solution with 
the gold nanoparticles at a ratio of 1000:1. The sulfur in the thiol compound covalently 
bonds to the gold nanoparticle surface, leaving the inert PEG corona to protect the 
nanoparticle, in a process known as PEGylation. In practice, variations in these PEG 
chains are included to tailor the chemical properties of the nanoparticles.  Here, 2 kDa 
methoxy-PEG-thiol (CH3O-(CH2CH2O)n-CH2CH2SH), with the chemically inert methoxy 
group, is mixed in a ratio of 98:2 with 5 kDa carboxymethyl-PEG-thiol                
(CH2COOH-(CH2CH2O)n-CH2CH2SH). The carboxymethyl-PEG-thiol is greater than 
twice as long, such that the carboxymethyl- group is exposed on the PEGYlated 
nanoparticle surface. The carboxymethyl- group is activated for conjugation to targeting 
ligands (Fischer 2010). In a common technique, repeated here, N-hydroxysuccinimide 
(NHS) is used with (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) 
(EDC) and several buffers to link proteins, such as monoclonal antibodies, to other 
molecules (Reist et al. 1999, Lewis et al. 2001, Fischer 2010, Bartczak and Kanaras 2011). 
In particular, anti-CD340 (ant-HER2) and EGFR (anti-HER1) were used to evaluate 
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specific and non-specific binding characteristics in the HER-2 positive SKBr3 cell line, 
similar to (Boskovitz et al. 2009). 
 
 
2.5.3 Characterization and Measurements 
 
Colloidal gold nanoparticles can be characterized by several methods. Two 
primary methods involve Transmission Electron Microscopy (TEM) and ultraviolet-
visible spectroscopy (UV-Vis).  Microscopic analysis consists of drying a sample of 
concentrated nanoparticles on a suitable sample grid, followed by TEM imaging. The 
resulting images are then analyzed using image analysis software, such as ImageJ, a tool 
provided through the NIH (Schneider et al. 2012). ImageJ was designed for analysis of 
medical DICOM images. The program can automatically create regions of interest (ROI), 
and can perform various measurement functions. The user can “calibrate” the software by 
measuring the standard included in the image. The user can also edit or manually add ROIs 
in images too complex for the built-in algorithm. The data from this analysis can be used 
to determine size distributions and to correlate number concentration, given the known 
volumes and masses used in the initial reaction.  An example of a TEM image showing ~ 
10 nm gold nanoparticles is provided in Fig. 27. 
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Figure 27. TEM images of approximately 11.6-23.5 nm diameter gold nanoparticles at 
different magnifications. Image analysis demonstrated a narrow particle size distribution. 
 
 
UV-Vis spectroscopy is equally useful for determining plasmonic nanoparticle 
characteristics. Plasmonic nanoparticles, including colloidal gold, exhibit characteristic 
surface-plasmon resonance (SPR) emissions as a function of size. Surface-plasmon 
resonance involves resonant oscillation of conduction electrons on the outer surface of the 
nanoparticle when excited by visible or near-visible light. On the macroscopic level, this 
is manifested in different colors of nanoparticle solutions as a function of nanoparticle 
size. As an example, solutions containing nanoparticles of different sized distributions are 
shown in Fig. 28; note the differences in colors for each solution. These samples are the 
same as presented in Fig. 25. 
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Figure 28. Nanoparticle solutions are shown of various sizes. Numbers on vials correlate 
to mM concentration of sodium citrate used in the formation reaction. 
 
 
At an analytical level, UV-Vis absorbance has been shown to be dependent upon 
both nanoparticle size and concentration (Haiss et al. 2007, Amendola and Meneghetti 
2009). Typically, the peak in light absorption, or SPR-peak, as a function of wavelength 
is dependent upon nanoparticle diameter. In addition, the relative magnitude and width of 
the SPR-peak provides information about concentration and the size distribution. Peak 
characteristics have also been shown to provide quantification of protein labelling and 
degree of conjugation (Kumar et al. 2008, Hamoui 2015). A miniaturized UV-Vis 
spectrometer, the NanoDrop 2000C (ThermoFisher Scientific, 168 Third Ave., Waltham, 
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MA 02451) was used in conjunction with commercially produced gold nanoparticle 
standards (Cytodiagnostics, 919 Fraser Drive Unit 11, Burlinton, ON, L7L 4X8, Canada) 
to develop an algorithm for determining nanoparticle size and concentration. These 
standards were supplied with NIST traceable certificates for nominal size and 
concentration. Particle sizes were verified with TEM image analysis. UV-Vis spectra, 
showing absorption peaks as a function of nanoparticle size, are shown in Fig. 29. 
Absorption peaks are shown as a function of nanoparticle diameter in Fig. 30. It is 
important to note that there is a red-shift of 3-5 nm in these values for nanoparticles 
following PEGylation and/or protein conjugation, as the added layer of material affects 
the surface refractive propertied (Kumar et al. 2008). 
 
Figure 29. UV-Vis absorbance as a function wavelength (nm) for different AuNP 
standards of 5, 10, 15, 20, 30, 40, 60, 80 and 100 nm in diameter. 
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Figure 30. Characteristic SPR-Peak wavelength is shown as a function of nanoparticle 
diameter. Nanoparticle standards of 5, 10, 15, 20, 30, 40, 60, 80 and 100 nm were verified 
by TEM image analysis. 
 
 
 
The molar concentration of gold nanoparticles for a given nominal diameter was 
calculated using the Beer-Lambert law expressed as 𝐴𝐴 = 𝜀𝜀𝜀𝜀𝜀𝜀, where 𝜀𝜀 is the extinction 
coefficient (M cm-1), b is the path length (cm), and C is the molar concertation (M), and A 
is the absorbance peak (a.u.). The extinction coefficients, ε, were determined using UV-
Vis spectroscopy for different particle sizes and surface ligands (Liu et al. 2007). The 
surface ligand in our case is trisodium citrate and the path length of the NanoDrop 2000C 
spectrophotometer is set at b = 1 cm.  These data are presented in Fig. 31. 
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Figure 31. Extinction coefficient, ε, as a function of nanoparticle diameter, d, estimated 
by Liu et al., and those calculated using the standards. 
 
 
 When considering nanoparticles used in vitro and in vivo, the hydrodynamic 
diameter of the particles affects circulation, retention, and cellular uptake (Kumar et al. 
2008, Jokerst et al. 2010). Hydrodynamic diameter represents the external diameter of the 
nanoparticle complex. Dynamic Light Scattering (DLS) is typically used to characterize 
this property, however, this instrumentation was not available. Hydrodynamic diameter 
was estimated based on similar procedures and results shown in the literature (Kumar et 
al. 2008, Chattopadhyay et al. 2010, Ting et al. 2010, Jokerst et al. 2011, Kim et al. 2011).  
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2.6 Radiological Safety 
 
 The wide range of situations involved in radionuclide production, 
radiopharmaceutical manufacturing, and in vitro experimentation present a diverse set of 
processes that must be performed safely. This is especially true in a university setting, 
where relatively untrained undergraduate students may be involved in the process, as well 
as graduate students and professionals (Martin and Akabani 2012). Experimentation using 
radioactive material in vitro is widely practiced, so will not be covered in detail herein. 
The focus will primarily be on radiological safety aspects during cyclotron production, 
and post-production processing. 
 
2.6.1 Cyclotron and Radiochemistry Facility 
 
Cyclotron facilities present many radiological hazards (IAEA 2009b). Of obvious 
concern is the intense gamma and neutron radiation fields produced when the cyclotron is 
operating. However, this hazard is largely mitigated through a series of radiation detectors, 
interlocks, and engineering and administrative controls (Zanzonico et al. 2008). Of equal 
concern, but somewhat less obvious, is the presence of highly activated targets and 
cyclotron equipment (Ogata et al. 2011). Again, this is somewhat protected against by 
radiation monitoring, shielding, and interlocks. The vast majority of activated products, 
which contribute to intense radiation fields, are short-lived, and decay away with half-
lives on the order of seconds or minutes (Martin and Akabani 2012). Common examples 
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include 28Al (T1/2 = 2.414 min) and 55Cr (T1/2 = 3.497 min). Shielding in the laboratory 
during recovery, well-practiced procedures, efficient workflow, and other considerations 
are critical for radiological safety in the radiochemical facility. 
 
 
2.6.1.1 Cyclotron Radiation and Activation Products 
 
In previous research, estimations of the amount and type of activation products, 
and their impact on exposure rate, were analyzed for the 209Bi (α, 2n) 211At reaction 
(Martin and Akabani unpublished data 2012, Martin et al. 2014). Briefly, estimated cross 
sections and outgoing particle spectra were calculated for all open reaction channels 
produced by 209Bi (α, X) reactions using the code TALYS (Koning et al. 2008). In order 
to approximate the total neutron production within a thick target, calculations were 
performed with alpha particle energies spanning the range of 0.001 MeV to 28 MeV. Many 
of the reaction channels resulted in negligible cross sections when compared to the 
primary reactions (α, 2n), (α, α’), (α, n), and (α, nα), listed in order of decreasing total 
yield. The neutron yield, angular dependence, and normalized differential cross sections 
produced by these data, Figs. (32-34), were used to create an input file for the transport 
code MCNPX (Martin et al. 2014).  
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Figure 32. The total neutron production cross section and average neutron yield for the 
209Bi (α, xn) reaction are shown as a function of incident alpha particle energy. Reprinted 
with permission from (Martin et al. 2014). 
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Figure 33. The differential cross section for neutron production is shown as a function of 
incident alpha particle energy on a 209Bi target. Reprinted with permission from (Martin 
et al. 2014). 
 
 
Activation analysis and dose rate analysis was performed using MCNPX (Pelowitz 
2008). This analysis was carried out on a representative target, as well as arbitrary blocks 
of common material found in the cyclotron facility, including stainless steel, aluminum, 
and concrete. Activation product mass concentration was estimated with these data, and 
applied to known equipment of interest within the target area. The neutron beam is 
strongly biased towards the forward direction, as a function of energy (e.g., higher energy 
incident alpha particles result in a higher magnitude of forward bias). Because of this, it is 
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expected that the majority of the activation occurs in a small cone shaped area, in-line with 
the ion beam. Scattered and moderated neutrons throughout the rest of the facility were 
neglected in this analysis, as this is commonly encountered during normal cyclotron 
operation. Neutron dose was calculated using the flux-to-dose conversion factors provided 
by the International Commission on Radiation Units and Measurements (ICRU) Report 
57, and was generally found to be negligible outside the cyclotron vault (ICRU 1998). 
 
 
 
Figure 34. The normalized neutron energy spectrum is shown for the 209Bi (α, xn) 
reaction. Reprinted with permission from (Martin et al. 2014). 
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Table 9 provides estimated yields of all significantly produced radionuclides, 
excluding radionuclides produced heavy charged particle interactions from the primary 
beam. Produced yields are given in terms of specific activity per integrated current. As 
can be seen, most activities are insignificant when compared to 24Na, 28Al, 55Cr, and 211At. 
 
 
Table 9. Calculated yields of significant radionuclide activation products as estimated 
using MCNPX. 
Radionuclide Half-life Specific Activity 
per Incident 
Particle 
(Bq α-1 kg-1) 
Specific Activity 
per Integrated 
Current 
(Bq μAp-1 h-1 kg-1) 
Primary 
Activated 
Material 
211At 7.214 h 2.89×10-7 6.92×109 Target 
     
28Al 2.414 min 1.15×10-10 2.75×106 Target holder, instrumentation 
51Cr 27.70 d 1.47×10-16 3.31×100 
Beam pipe, 
structural 
supports 
55Cr 3.497 min 7.84×10-13 1.76×104 
56Mn 2.579 h 2.38×10-14 5.35×102 
55Fe 2.730 y 4.89×10-18 1.10×10-1 
59Fe 44.50 d 1.33×10-17 2.99×10-1 
24Na 14.96 h 9.54×10-16 2.14×101 
Concrete 
structure, 
shielding, wall 
plugs, etc. 
27Mg 9.458 m 7.90×10-16 1.77×101 
49Ca 8.718 m 1.60×10-17 3.59×10-1 
51Ti 5.760 m 3.71×10-16 8.34×100 
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Following the end of irradiation of the target, it is customary to allow a so-called 
“cooling time” on the order of 15-30 minutes to allow the intense, short-lived activation 
products decay. The dose received by a worker, especially when a target must be manually 
manipulated, is significantly reduced by this brief waiting period (Zanzonico et al. 2008, 
Martin and Akabani 2012). 
 
 
2.6.1.2 Radiochemistry Facility 
 
  It is important to incorporate standard safety considerations into the 
radiochemistry facility design. Shielding of waste containers and work areas, air handling 
and monitoring (discussed in the next section), access control to restricted areas, and 
proper equipment for reducing direct manipulation of the target or product are essential 
(IAEA 2009b).  
 The IRBRB has incorporated a shielded hot cell, two shielded chemical enclosures, 
and a shielded fume hood to provide adequate protection to personnel during recovery 
(Von Gahlen International Inc., P.O. Box 1550, Chatsworth GA 30705). The dual 
chemical enclosures and hot cell, equipped with remote manipulator arms, are designed 
with 3-inch lead shielding and are suitable for high-level production of positron emitting 
radionuclides. A view of the hot cell is provided in Fig. 35. While this level of shielding 
is overly protective for the low gamma emissions of 211At, an end goal of the IRBRB is to 
pursue production of positron-emitting radionuclides, such as 64Cu and 62Zn/62Cu, for 
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research in PET imaging and theranostics. However, the filtered ventilation provided by 
these units is ideal in preventing facility contamination via airborne alpha emitters, as 
produced in this study. The dual chemical enclosures, while not in use for processing, are 
currently configured to hold calibration sources, thereby reducing their influence on 
background, as well as holding high-dose-rate waste, such as the target backing and other 
activated components. 
The shielded fume hood, actually a biological safety cabinet (BSC), shown in Fig. 
16 and Fig. 36, provides 1.5-inch lead shielding on the sides, bottom, and rear of the 
device. An additional sliding shield, with 1.5-inch equivalent leaded glass, is used to 
provide shielding to the front of the worker. The fume hood is designed exclusively for 
use with the furnace and equipment dedicated to 211At production. Filtration by high 
efficiency particulate air (HEPA) filters and activated carbon is provided to capture and 
release of radioactivity. Extensive shielding is not necessary for the astatine itself, but is 
beneficial for reducing the dose rate due to activated 28Al in the target backing plate during 
distillation. 
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Figure 35. The hot cell, featuring remote manipulator arms, is shown. Note the control 
(lower right) for the dose calibrator (inside). Doors to the dual chemical enclosures are 
just visible to the left of the image. 
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Figure 36. The fume hood with movable front shield is shown. Detection and assay 
equipment are visible to the left of frame. 
 
 
 Workflow and other considerations can also lead to decreased dose to the worker. 
For example, removal of the bismuth/astatine matrix from the aluminum target backing 
for distillation not only decreases the distillation time, but also allows the activated 
aluminum to be placed in a shielded container. Performing preliminary steps prior to 
elution or astatination also reduces absorbed dose to both the user, as well as equipment. 
While chemistry module components are mostly made of radiation resistant materials, 
such as PEEK, long-term exposure will cause a degradation of materials (Anaheim et al. 
2015a). 
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2.6.2 Air Handling and Facility Air Monitoring 
 
Air handling and air quality play an important role in meeting standards for 
compliance in sterility and purity. In general, radiopharmaceuticals, especially 
immunoconjugates, cannot be heat sterilized prior to patient administration. This places a 
high importance on aseptic procedures and equipment (IAEA 2009c). Additionally, the 
establishment of a clean room environment is necessary for meeting future cGMP and 
USP requirements (US FDA 2009). With this in mind, the radiochemistry room of the 
IRPRP was designed and tested to as-built ISO Class 7 cleanroom standards as per the 
ISO 14644-1 classification system. These standards dictate particulate size and 
concentration standards, as detailed in Table 10. A schematic of the room is shown in Fig. 
37. 
To fulfill the as-built Class 7 standards, several system components are 
incorporated. These segments include air inlet and exhaust, differential room pressure, 
anteroom design, and non-permeable surfaces. At-rest and operational standards will 
require additional training on gowning and disinfecting procedures. 
Conditioned inlet air is passed through several HEPA filters in parallel to both 
purify the incoming air and meet minimum volumetric exchange rates. Air intake occurs 
at the ceiling, and is exhausted by ducts near floor level. In this particular installation, 
room exhaust is also provided by continuous flow through a laminar flow hood or 
biological safety cabinet. 
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Table 10. Limits on particle concentration as a function of aerodynamic diameter are 
given for as-built ISO clean room standards. 
ISO Class Particulate Concentration by Aerodynamic Diameter, m-3 
5 μm 1 μm 0.5 μm 0.3 μm 0.2 μm 0.1 μm 
ISO 1  (10*0000) -- -- -- -- 2.37×100 1.0×101 
ISO 2  (10*0000) -- -- 3.52×100 1.02×101 2.37×101 1.0×102 
ISO 3  (1)*00000 -- 8.32×100 3.52×101 1.02×102 2.37×102 1.0×103 
ISO 4  (10)*0000 -- 8.32×101 3.52×102 1.02×103 2.37×103 1.0×104 
ISO 5  (100)*000 2.93×101 8.32×102 3.52×103 1.02×104 2.37×104 1.0×105 
ISO 6  (1000)*00 2.93×102 8.32×103 3.52×104 1.02×105 2.37×105 1.0×106 
ISO 7  (10000)*0 2.93×103 8.32×104 3.52×105 -- -- -- 
ISO 8  (100000)* 2.93×104 8.32×105 3.52×106 -- -- -- 
ISO 9  (100000)* 2.93×105 8.32×106 3.52×107 -- -- -- 
* Numbers in parentheses represent the approximate Class as defined by US Federal Standard 209E 
 
 
Product open to the atmosphere must be manipulated within an ISO Class 5 
environment. In the IRPRP installation, the shielded BSC and a specially filtrated hot cell 
and chemistry module enclosure meet this standard. The BSC is a commonly available 
unit from Labconco, which has been modified by the shielding vendor Von Gahlen. The 
Universal Hot Cell and Dual Chemical Enclosure modules are also provided by Von 
Gahlen. Inlet and exit HEPA filtration is provided in both units. The hot cell and chemistry 
module enclosure also contains an activated charcoal filter canister for exhaust scrubbing. 
The BSC and clean room exhaust pass through a large activated charcoal filter on the roof 
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of the facility prior to final exhaust. The HEPA exhaust filters are provided to remove 
radioactive particulates entrained in the exhaust, while the activated charcoal provides 
filtration of vapors. 
An anteroom is provided for several purposes. Primarily, the anteroom acts as a 
barrier between the clean room and the unclassified space, as detailed below. Additionally, 
the anteroom provides a convenient location for gowning, a step-off pad, hand-and-foot 
contamination monitors, as well as storage of PPE when not in use. 
Air quality is preserved by maintaining pressure differentials between rooms. 
Standard guidance is to maintain the clean room at a positive relative pressure, such that 
no contamination enters the room via penetrations or door openings. However, the IRPRP 
radiochemistry room is located in a facility that sees a large amount of research in others 
and has a correspondingly large traffic of cyclotron personnel, faculty, and students. The 
Radiological Safety Staff at Cyclotron Institute therefore required the room to be at 
negative pressure relative to the remainder of the facility, such that any airborne 
contamination would remain isolated in the IRPRP. 
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Figure 37. A schematic of the radiochemistry room floor plan is provided, showing 
locations of conditioned air inlet through HEPA filters, floor level return ducts (R), and 
approximate location of the hot cell and biological safety cabinet (BSC). 
 
 
Facility effluent air monitoring in place at the Texas A&M Cyclotron Institute is 
optimized for the entire facility, and is not conducive to detecting alpha emitting 
radionuclides. Due to the potential of airborne release, based upon the volatility of astatine, 
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as well as the dry distillation operation, dedicated area monitoring and effluent monitoring 
equipment were installed in the IRPRP radiochemistry facility. Area radiation monitoring 
for gamma and x-ray radiation is provided by a Canberra G64 Area Gamma Monitor 
(Canberra Inc., 800 Research Pkwy, Meriden CT 06450). This unit consists of a solid state 
detector, and incorporates building power and is connected to the cyclotron control room 
alarm system. Air effluent monitoring is provided by a Canberra iCAM Alpha/Beta Air 
Monitor. Air exhaust from the hot cell and BSC are routed through the detector. Air is 
drawn through the device by a vacuum pump. Any airborne particulates are deposited onto 
removable filter material, which is changed monthly, or after every processing experiment. 
The filter is monitored on-line via a passivated implanted-ion planar silicon (PIPS) 
detector, which provides counts in separate alpha and beta channels. As with the G64, this 
unit is tied into building power, as well as the building alarm control panel. Additionally, 
logic circuits and automatic controls are driven by the iCAM. Air inlets to the room, 
exhaust fans, dampers, and a roof mounted blower are all controlled by the automated 
logic. In the event of an airborne release, the iCAM is programmed to provide an alarm 
over a specified threshold count level. This will drive the logic system to maintain negative 
pressure in the radiochemistry laboratory to contain the airborne release. The system will 
also minimize exhaust, and route the remaining exhaust through a large volume activated 
charcoal filter on the roof of the facility, preventing the release of the airborne contaminant 
to a public area. The G64 and iCam are shown in Fig. 38. Also visible are some of the 
logic controllers and sensors used to control the airflow state. 
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Figure 38. The facility radiation monitors are shown. On the left is the iCAM model 
continuous particulate air monitor. On the right is the G64 model area gamma alarm. 
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3. RESULTS 
 
A series of five individual experiments were conducted to produce 211At.  
Extended (8+ h) overnight irradiations of 29 MeV (7.25 MeV u-1) alpha particles at 
currents up to 7 μAe were performed with satisfactory results. Production yields ranged 
between 10.73 – 39.17 MBq µAp-1 h-1, consistent with published yields, at average beam 
intensities on the order of 5-10 times that used in previous experiments (2-3 µAp). 
Recovered yields were on the order of 20 mCi per production run after initial development 
(median 22.09 mCi ± 0.77). No contamination by 210At or 210Po was detected in any of the 
recovered product, however, 135I contamination was suspected prior to distillation in two 
samples. The total time involved for each experiment, including irradiation and post-
processing, ranged from 18-24 hours. Irradiations were performed overnight on weekdays, 
such that a full complement of health physicist and cyclotron personnel would be available 
to help during the distillation and recovery phase of experimentation.  
Beam development was performed by experienced Cyclotron Institute staff, using 
a phosphor plate. While it is preferable to tune the beam and then irradiate a piece of 
radiographic film placed on the target holder, this option was not available due to the lack 
of a nearby vacuum isolation valve. The nearest isolation valve isolated approximately 
thirty linear feet of beam line, the target enclosure, and the volume involving a large 
bending magnet leading to other experiment ports. The time involved in purging, and then 
pulling down the pressure on this large volume made beam characterization impractical. 
However, a phosphor plate was used to roughly position the beam and adjust focusing. 
 111 
 
Upon irradiation, the target and target backing phosphoresced and the beam spot was 
visible on a black and white CCD camera closed circuit television image. This camera was 
used to validate beam placement and size, as well as to monitor the target for physical 
signs of melting and deformation during all experiments.  
The initial experiment was used as a proof of production. A water chiller was not 
available during this run, and the maximum current was therefore limited. Distillation did 
not occur for this first experiment. A water chiller operating at 4 °C and 1.5 L min-1 flow 
rate was used to cool the target on all other production runs. Thermocouple measurements 
at the target holder showed a steady state temperature of 11 °C, prior to irradiation, which 
was consistent from across all experiments. Temperature was not measured on-line, as 
remote connections for the thermocouple were not available. Table 11 shows a comparison 
of the produced yields from these experiments, compared to published results (cf Table 
4). A summary of the produced yield, decay corrected to EOB, is provided in Table 12. 
Also shown is the total product activity of 211At for each run. Table 13 shows the decay 
corrected distillation yields for each experiment, in terms of RCP and RCY, as well as a 
comparison to published data. Detailed results of each experiment are given individually 
in the following paragraphs. Unless otherwise stated, errors are quoted as standard error, 
and activities are decay corrected to EOB. 
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Table 11. Produced yields are shown for these experiments, compared to published 
results. 
211At Yield EOB 
(MBq μAp-1 h-1) 
Experimental Published 
Minimum 10.7 4 
Maximum 39.2 48 
Median 27.5 12.4 
 
 
 
 
Table 12. Yields and EOB activities are shown for the experimental production runs. 
Exp. 
No. 
211At Yield EOB                                   
(MBq μAp-1 h-1) 
211At Activity
EOB 
(MBq) 
211At Activity 
EOB 
(mCi) 
RCY 
(%) 
Exp. 1 -- -- -- -- 
Exp. 2 10.7 ± 0.101 011.71 ± 3.4 00.316 ± 0.094 21.13 ± 29.05  
Exp. 3 39.2 ± 0.103 817.5 ± 80.2 22.09 ± 2.17 55.79 ± 17.68 
Exp. 4 29.0 ± 0.100 847.6 ± 35.4 22.91 ± 0.96 50.63 ± 1.17 
Exp. 5 26.0 ± 0.102 790.5 ± 21.8 21.36 ± 0.59 62.00 ± 3.08 
Median 27.5 ± 0.203 804.0 ± 90.4 21.72 ± 2.45 53.21 ± 34.17 
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Table 13. Radiochemical yield data for each experiment is compared to published RCP 
and RCY values. 
Experiment RCP (%) RCY (%) 
#1 -- -- 
#2 99.999 ± 6.036 21.128 ± 29.049 
#3 99.964 ± 2.672 55.8 ± 9.81 
#4 99.980 ± 0.024 50.63 ± 1.17 
#5 99.992 ± 3.157 62.00 ± 3.08 
Groppi et al. 2005 99.96+ 60-80 
Hadley et al. 1991 98+ 30 ± 18.9 
Yordanov et al. 2001 -- 60 
Schwarz et al. 1998 -- 68 
 
 
 
3.1 Experiment 1 
 
 Experiment 1 was performed as a preliminary test experiment. The new target 
system, as seen in Fig. 9, had not been used prior to this experiment. Additionally, the K-
150 cyclotron had not been used in any 211At production experiments, and the water chiller 
was not available due to scheduling conflicts. Finally, this experiment was before 
implementation of the clamping system used to hold the target backing to the target holder. 
Because of this, the maximum allowable beam current on target was severely limited. An 
initial beam of 28.88 MeV (7.22 MeV u-1) and 2.1 μAe was used to bombard the target. 
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The bismuth showed signs of melting within 2 minutes. A faraday cage was placed while 
the current was adjusted to 0.4 μAe. A short amount of time (2 min) was given for the 
target to cool, followed by irradiation at 0.4 μAe. for 37 minutes. The target again showed 
signs of melting, so the beam current was reduced to 0.2 μAe. The target was irradiated 
for an additional 9 hours and 20 minutes, giving a total integrated current of approximately 
1.09 μAp-hr. After a 30-minute cool down time, dose rate measurements were taken using 
an ion chamber (Fluke 451P). The target, in the holder, measured approximately 5 mR hr-
1 on contact with the vacuum enclosure. A picture of the beam line entering the vacuum 
enclosure is given in Fig. 39. A view from the top of the vacuum enclosure, looking down 
onto the target face, is shown in Fig. 40. This target was allowed to decay and was not 
processed in the radiochemistry facility. 
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Figure 39. A view of the target vacuum enclosure. The beam line enters from the left. 
Note the shield wall to the right. The target is accessed by removing the screws and side 
plate facing the camera. 
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Figure 40. A view from the top of the vacuum enclosure, looking down on the target, 
located by the red arrow. The beam enters from the right. 
 
 
3.2 Experiment 2 
 
 Experiment 2 was conducted utilizing the water chiller and new style clamps 
during irradiation. The pyramidal indentions in the target backing were not incorporated, 
and thermal grease was not used. A picture of the target prior to irradiation is shown in 
Fig. 41, highlighting the new clamping system.  
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Figure 41. The new target clamping system is shown. BNC connectors visible behind the 
target are for beam tuning instrumentation. 
 
 
 Beam current during Experiment 2 was periodically increased in an effort to 
determine the maximum allowable current. The water chiller was used to bring the target 
to a steady state temperature of 11 °C before irradiation. Temperature was not measured 
during irradiation. Beam energy was the same as Experiment 1: 28.88 MeV                      
(7.22 MeV u-1). Beam current on target as a function of time is provided in Table 14. The 
total integrated current for Experiment 2 was approximately 4.78 μAp-hr, better than four 
times that in Experiment 1. 
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Table 14. Beam current as a function of time is tabulated for Experiment 2. 
Time on Target 
(hh:mm) 
Beam Current 
(μAe) 
Notes 
00:00 0.37  
00:03 -- Ion gauge malfunctioned. Vault opened to reset. 
00:20 0.42  
00:32 0.60  
00:42 0.80  
00:52 1.00  
01:03 1.20  
01:11 1.60  
01:27 2.00  
01:28 -- Beam stopped. Signs of melting. 
01:39 1.00 Beam restarted. 
10:04 -- EOB 
 
 
 After a 30-minute cooling time, the target was removed and transported to the 
radiochemistry laboratory for processing. The target was counted by HPGe at the 2 m 
location, with tabulated yield data shown in Table 15. Difficulties in setting up the 
distillation apparatus and other factors delayed the onset of distillation by approximately 
an hour and a half. Several items were noted during this initial recovery work for 
improvements in timing and efficiency in further experiments. Distillation was begun, 
with a programmed maximum furnace temperature of 700 °C. Target temperature 
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increased, as measured with an infrared thermometer, and the furnace temperature was 
reset to 650 °C. After 42 minutes at this temperature, the furnace was ramped back to 700 
°C, as it was noted that bismuth in the far end of the crucible was not molten. This 
observation emphasized the need for proper target placement in future experiments. 
During distillation, activity in the cold trap was measured both by the dose calibrator and 
with a Geiger-Mueller (G-M) probe located near the cold trap entrance. The dose 
calibrator did not provide meaningful readings, indicating that the geometry in use was 
incompatible with this detector. The temperature profile and G-M count rate are shown as 
a function of time in Fig. 42. 
 
 
Figure 42. Count rate and furnace temperature data are shown for experiment two during 
distillation. 
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At the end of distillation, measurements were made of the charcoal filter, the PEEK 
tubing in the cold trap, and the target. The amount remaining in each item is tabulated in 
Table 16. Note that 28Al and other contaminants are likely present in the target, 
contributing to the measured count rate. It is not clear why a large amount of activity 
remained in the target. The target and quartz tray used during distillation are shown in Fig. 
43. The quartz tray cracked upon cooling, most likely due to uneven contraction. Note that 
the aluminum target backing appears melted in places, and the entire target is charred. It 
was decided to increase the furnace temperature for future experiments. 
 Following distillation, the PEEK capillary was washed twice with 2 mL of sodium 
citrate solution, and captured in a 5-mL vial. This sample was placed in the 10 cm counting 
location and counted for 20 minutes. Calculated yields based on spectral data for a two-
hour count from the aliquot are presented in Table 17. No contamination by 210At or other 
radionuclides was detected, although recovered yield was very low. 
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Table 15. The calculated yields based on spectral data are provided for the target of 
Experiment 2, prior to distillation. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
(%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 932 4.5 16.5 ± 2.8 0.45 ± 0.077 
211Po 
569.7 1343 0.3 11.1 ± 1.5 0.30 ± 0.042 
897.8 820 4.4 07.5 ± 1.3 0.21 ± 0.035 
Median 211At/211Po 11.71 ± 3.4 0.316 ± 0.094 
210At 
245.3 -- -- -- -- 
1181.4 -- -- -- -- 
1436.7 -- -- -- -- 
1483.4 -- -- -- -- 
1599.5 -- -- -- -- 
 
 
 
Table 16. Recovered count rate fractions post-distillation for Experiment 2. 
Location Percent Count Rate 
Target 92.5 
Cold Trap 02.9 
Charcoal Filter 04.6 
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Figure 43. The target/target backing and quartz tray for Experiment 2 are shown after 
distillation. 
 
 
Table 17. The calculated yields based on spectral data are provided for the final sample 
from Experiment 2, decay corrected to EOB. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
 (%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 2920 2.1 4.089 ± 0.087 0.1105 ± 0.0023 
211Po 
569.7 4220 1.7 2.474 ± 0.042 0.0669 ± 0.0011 
897.8 2890 1.9 2.255 ± 0.043 0.0609 ± 0.0012 
Median 211At/211Po 2.474 ± 0.106 0.0669 ± 0.0028 
Median 210At -- -- 
RCP 211At/211Po (%) 99.999 ± 6.036 
RCY 211At/211Po (%) 21.128 ± 29.049 
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3.3 Experiment 3 
 
Experiment 3 used the water chiller and new style clamps during irradiation. In 
addition, the pyramidal indentions in the target backing and thermal grease between the 
target holder and target backing plate were incorporated. As can be seen in Table 18, these 
changes allowed for a substantial increase in beam current on the target. Beam energy 
remained at 28.88 MeV (7.22 MeV u-1), with an approximate total integrated current of 
20.87 μAp-hr. 
Similar distillation procedures were followed as in previous experiments. The 
furnace temperature was preset to 950 °C to ensure full target melting, in an attempt to 
increase recovery. The target bismuth/astatine matrix was able to be separated from the 
aluminum target backing plate for distillation. The cold trap arrangement was altered for 
this distillation. Instead of submersion in liquid nitrogen within the dose calibrator well, a 
small plastic bucket was used with a mixture of ethanol and dry ice at -72 °C. Larger 
diameter coils of the capillary tubing were submerged in this bath, with a G-M detector 
placed next to the bucket. Count rate data from the G-M detector and target temperature 
data are provided as a function of time in Fig. 44. 
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Table 18. Beam current as a function of time is tabulated for Experiment 3. 
Time on Target 
(hh:mm) 
Beam Current 
(μAe) 
Notes 
00:00 1.00  
00:09 1.50  
00:20 1.75  
00:30 2.0  
00:40 2.30  
00:55 2.50  
01:06 2.80  
01:11 3.10  
01:16 3.50  
01:21 3.75  
01:26 4.00  
01:33 4.50  
01:38 5.00  
01:43 5.50 Vault neutron monitor at 2146 mR hr-1 
01:50 5.00 Reduced to 5.0 μAe for overnight. 2129 mR hr-1 
05:20 5.00 Noticed wandering in current. Reset to 5.0 μAe. 
09:10 0.00 EOB 
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Figure 44. Count rate and furnace temperature data are shown for experiment three during 
distillation. 
 
 
 A background corrected spectrum of the target and target backing prior to 
distillation is shown in Fig. 45. As can be seen, there are impurities present. The lines 
present at 511 keV and 1275 keV indicate that one contaminant is 22Na (T1/2 = 2.602 y, 
y511 = 1.81, y1273.6 = 0.99), likely a contaminant from the aluminum backing plate or 
activation of a component of the thermal grease. However, the relative number of counts 
between the 22Na photopeaks do not correlate to the published yields. Therefore it is likely 
that annihilation radiation from another source is also present. Other impurity gamma lines 
at approximately 1039 keV and 1368 keV could likely correspond to 135I (T1/2 = 6.57 hr, 
y1038.8 = 0.08, y1367.9 = 0.06). The source for this radionuclide is unclear, but likely comes 
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from activation of the thermal grease. Initial target yields for products are shown in Table 
19, with impurity yields shown in Table 20. 
 
 
Figure 45. The gamma spectrum of the target for Experiment 3 prior to distillation. 
 
 
Table 19. Calculated yields based on spectral data are provided for the target prior to 
distillation from Experiment 3. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty  
(%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 464 05.3 1222 ± 65.7 33.05 ± 1.78 
211Po 
569.7 681 04.2 817.4 ± 34.8 22.09 ± 0.94 
897.8 476 04.7 631.7 ± 30.1 17.07 ± 0.81 
Median 211At/211Po 817.5 ± 80.2 22.09 ± 2.17 
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Elution from the new cold trap apparatus was finished in several steps. Prior to 
elution, one-minute G-M measurements of the cold trap showed 1318 ± 62 counts. The 
capillary was removed from the cold trap, and an initial flush with 2 mL of ethanol was 
washed back and forth through the capillary three times, prior to recovery in a 5 mL empty 
vial.  One minute G-M measurements of the capillary coils after this flush averaged       
1295 ± 51 counts. This suggested that negligible astatine was eluted, and was likely 
retained in the PEEK due to low temperature. The tubing was allowed to warm for several 
minutes, followed by the same washing procedures, using the same 2 mL of ethanol. One 
minute counts taken after the washing averaged 1314 ± 63 counts, essentially the same as 
the previous readings. Finally, the PEEK tubing was washed with 2 mL of sodium citrate 
solution, yielding an average cold trap count rate of 481 ± 38 counts, or approximately 
37% of the average initial readings. The 5 mL vial containing the 4 mL mixture of ethanol 
and sodium citrate was counted in both dose calibrators using the 99mTc dial value (37.1), 
resulting in yields of 29.2 μCi and 30.4 μCi (average = 29.8 μCi).  
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Table 20. Estimated yields of contaminants are shown for the target prior to distillation 
from Experiment 3. 
Radionuclide 
Eγ 
 
keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
 (%) 
Activity 
 
(MBq) 
Activity 
 
(μCi) 
210At 245.3 -- -- -- -- 
 1181.4 -- -- -- -- 
 1436.7 -- -- -- -- 
 1483.4 -- -- -- -- 
 1599.5 -- -- -- -- 
Median 210At -- -- 
22Na 
511.0 708 04.7 2.124 ± 0.101 57.39 ± 2.73 
1273.6 43 12.1 0.401 ± 0.049 10.81 ± 1.33 
Median 22Na 1.262  ± 0.112 34.10 ± 3.04 
135Ia 
1038.8 38 18.1 4.158 ± 0.763 112.4 ± 20.6 
1367.9 25 22.3 3.873 ± 0.875 104.7 ± 23.7 
Median 135Ia 4.015 ± 1.161 108.5 ± 31.4 
a. Possible contaminant identity 
 
 
Following elution, the 5-mL sample vial was counted with the HPGe detector at 
the close position, while the remaining target activity was sealed in a plastic bag and 
shielded by the hot cell. Estimated yield calculations following elution are shown in Table 
21, with a spectrum shown in Fig. 46. The retained target was counted using the HPGe 
approximately 13 hours after the initial target assay. This long delay was an attempt to 
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characterize the impurity radionuclides by half-life. The change in activity of the 22Na was 
negligible, as expected with a 2.602 y half-life. However, the number of counts at 511 keV 
still exceeded the number of counts at 1273 keV by approximately a factor of 10. This 
suggests the presence of annihilation radiation from a separate unknown source, with a 
half-life significantly greater than 13 hours. The 135I half-life was estimated as 6.42 hr for 
the 1038.8 keV line, and as 4.61 hr for the 1367.9 keV line. Given the variance in the 
estimated activity seen in Table 18, and the nearness of the calculated value to the 
published value of 6.57 h (2.3 % and 29.8 %), the presence of 135I was confirmed with 
some confidence.  An additional benefit of the 13-hour delay was an attempt to measure 
the in-growth of 135Xe. Iodine-135 decays into radioactive 135Xe (T1/2 = 9.14 hr), a well-
known process that results in xenon precluded startup in nuclear reactors (Stacey 2004). 
Xenon-135 has several gamma emissions, with a predominant peak at 249.8 keV (y249.8 = 
0.9). None of the 135Xe peaks were detected after counting, leading to the conclusion that 
the supposed 135I was another radionuclide, or that the 135Xe could escape the plastic bag 
enclosing the target. No 210At impurity was present in the distillation sample, and only 
trace amounts of 135I were detected, resulting in RCP = 99.964 ± 2.672 % and RCY =   
55.79 ± 17.68 %. 
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Figure 46. The gamma spectrum of the distillation aliquot from Experiment 3 is shown. 
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Table 21. Calculated yields based on spectral data are provided for the distillation aliquot 
for Experiment 3, including RCP and RCY. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
 (%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 12600 01.05 665.5 ± 7.04 17.99 ± 0.19 
211Po 
569.7 18500 00.82 456.3 ± 3.76 12.33 ± 0.10 
897.8 12600 00.94 346.2 ± 3.25 09.36 ± 0.09 
135I 
1038.8 83 22.49 0.186 ± 0.042 0.0050 ± 0.0011 
1367.9 45 27.42 0.143 ± 0.039 0.0039 ± 0.0011 
Median 211At/211Po 456.3 ± 8.62 12.33 ± 0.23 
Median 135I 0.164 ± 0.057 0.0044 ± 0.0015 
RCP 211At/211Po (%) 99.964 ± 2.672 
RCY 211At/211Po (%) 55.79 ± 17.68 
 
 
 
3.4 Experiment 4 
 
The setup for Experiment 4 was identical to Experiment 3. The aluminum target 
backing for this experiment was made from high purity aluminum, obtained from the 
Cyclotron Institute, in an effort to remove 22Na contaminants. Having gained confidence 
in target integrity from the previous run, Experiment 4 was run at slightly higher currents, 
that were stepped up to the maximum at a greater rate, resulting in a higher integrated 
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current of 29.19 μAp-hr at 28.88 MeV (7.22 MeV u-1). After a brief step-up regimen during 
the first hour, the target was irradiated for better than 7.5 hours at 6.9 μAe. 
The gamma spectrum for the target and target backing prior to distillation is shown 
in Fig. 47. Yield calculations based on the gamma spectrum are given in Table 22. The 
pyramidal indentations made it extremely difficult to separate the bismuth/astatine matrix 
from the aluminum backing plate, so they were counted together. Clear product gamma 
emissions are visible, with no visible contribution by 210At. However, several impurity 
peaks not seen previously were present, at approximately 833 keV, 1038.8 keV, 1106.8 
keV, and 1368.0 keV. The peaks at 1038.8 keV and 1367.9 were likely the 135I 
contamination, as seen previously. The remaining peaks did not provide any definitive 
identification. Possible radionuclides are given in Table 23. 
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Figure 47. The gamma spectrum of the target and backing prior to distillation is shown 
for Experiment 4. 
 
 
Table 22. Calculated yields based on spectral data are provided for the target prior to 
distillation from Experiment 4. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
 (%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 2710 2.58 1112.7 ± 29.2 30.45 ± 0.79 
211Po 
569.7 3730 2.11 724.1 ± 15.3 19.57 ± 0.41 
897.8 3920 1.53 847.6 ± 12.9 22.91 ± 0.35 
Median 211At/211Po 847.58 ± 35.37 22.091 ± 0.956 
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Table 23. Impurity gamma emissions and possible sources are shown (NNDC 2016). 
Eγ 
(keV) 
Radionuclide 
Eγ 
(keV) 
yγ  
(Fraction) 
T1/2 
833.0 54Mn 834.8 1.00×100 312.2 d 
1038.8 135I 1038.8 7.95×10-2 6.57 hr 
1106.8 69Ge 1107 3.60×10-1 39.05 hr 
1367.9 135I 1367.9 6.08×10-3 6.57 hr 
 
 
 Distillation followed the same general procedure as for Experiment 3, with a 
temperature ramp to 950 °C. However, in this case, the aluminum target backing remained 
attached to the bismuth/astatine target during distillation. Count rate and temperature are 
given as a function of time in Fig. 48. The same capillary tubing used in Experiment 3 was 
reused. After starting the furnace and submerging the coils in the cold bath, it was noticed 
that the flow had stopped, indicated by the lack of bubbles in the bubble trap, 
approximately 4 minutes after the process began. The coils and bubble trap were removed 
from the cold bath and allowed to warm until flow resumed. Intermittent flow stoppages 
occurred until sufficient warm argon had flowed through the tubing to warm it or elute the 
remaining solution within the tube. A full blockage again occurred at 24 minutes. After 
warming the capillary coils, the count rate significantly increased, indicating the 
volatilization of the astatine. 
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Figure 48. Count rate and furnace temperature data are shown for Experiment 4 during 
distillation. Blockages occurred in the cold trap coils at 4 minutes and 24 minutes, 
impeding argon flow. 
 
 Following successful distillation, elution occurred using 2 mL of sodium citrate 
solution, followed by a second wash of the same volume. The solution was collected into 
a 5 mL vial. Net count rate in the capillary tubing decreased from 9184 ± 192 to 1670 ± 
58 during elution, correlating to an initial estimate of recovery of approximately 92%. The 
sample aliquot was counted with the HPGe in the close position. A spectrum is shown in 
Fig. 49, with tabulated yields in Table 24. The unknown peaks at 833.0 keV and 1106.8 
keV were not distilled. A small fraction of 135I was distilled, and no measurable 210At was 
detected. This resulted in an RCY  of 50.63 ± 1.17. 
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Figure 49. The gamma spectrum of the sample for Experiment 4 is shown after 
distillation. 
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Table 24. Calculated yields based on spectral data are provided for the sample after elution 
from Experiment 4. 
Radionuclide 
Eγ 
(keV) 
Peak 
Area 
(Counts) 
Peak 
Uncertainty 
(%) 
Activity 
(MBq) 
Activity 
(mCi) 
211At 687.0 7870 1.35 623.53 ± 8.42 16.85 ± 0.23 
211Po 
569.7 11600 1.05 429.18 ± 4.51 11.60 ± 0.12 
897.8 8020 1.16 330.50 ± 3.82 08.93 ± 0.10 
135I 
1038.8 33 25.15 0.110 ± 0.028 0.0030 ± 0.0007 
1367.9 13 35.46 0.062 ± 0.006 0.0017 ± 0.0006 
Median 211At/211Po 429.18 ± 10.29 11.59 ± 0.28 
Median 135I 0.086 ± 0.035 0.0023 ± 0.0009 
RCP 211At/211Po (%) 99.980 ± 0.024 
RCY 211At/211Po (%) 50.63 ± 1.17 
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3.5 Experiment 5 
 
The setup for Experiment 5 was identical to Experiment 4, including the new target 
backing. This new backing prevented the 22Na contamination found in the previous 
experiment, and showed excellent thermal qualities. The target was quickly stepped to a 
maximum beam current of 6.5 μAe at 28.88 MeV (7.22 MeV u-1), and was irradiated for 
nearly 9 hours, resulting in an integrated current of 30.37 μAp-hr. The target was firmly 
attached to the aluminum backing plate, so these components were assayed and distilled 
together.  
The gamma spectrum prior to distillation is shown in Fig. 50, with initial yield 
calculations in Table 25. As can be seen, some impurity peaks are apparent, including at 
approximately 203 keV, 245 keV, and 511 keV. Also visible is the 40K peak at 1650 keV. 
The source of the 203 keV and 511 keV is unknown. The 245 keV peak is indicative of 
210At, although other dominant 210At peaks (1181 keV, 1436 keV, 1483 keV, 1600 keV) 
are not visible. 
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Figure 50. The gamma spectrum of the target for Experiment 5 is shown prior distillation. 
 
 
Table 25. Estimated yields are shown prior to distillation for the Experiment 5 target. 
Radionuclide 
Eγ 
(keV) 
Peak 
Area 
(Counts) 
Peak 
Uncertainty 
(%) 
Activity 
(MBq) 
Activity 
(mCi) 
211At 687.0 6729 1.43 1250.6 ± 17.85 33.80 ± 0.48 
211Po 
569.7 10160 1.10 790.5 ± 8.72 21.37 ± 0.24 
897.8 6903 1.25 714.9 ± 8.93 19.32 ± 0.24 
Median 211At/211Po 790.5 ± 21.78 21.36 ± 0.59 
210At 245.3 391 8.73 0.069 ± 0.006 0.002 ± 0.0002 
Unknown 511.1 435 11.77 -- -- 
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 New capillary tubing was used during the distillation for Experiment 5. The target 
and backing plate were heated together. The distillation procedure followed was the same 
as previously. Count rate plateaued for a significant amount of time. The cold trap coils 
were removed from the bath 55 minutes after the distillation began, as noted by the vertical 
line in Fig. 51. As the coils warmed, the count rate increased significantly, indicating that 
there was a partial blockage of the tubing. 
 After distillation, the coils were washed twice with 2 mL volumes of sodium citrate 
into a 5 mL vial. Counting occurred using the HPGe in the close position. The spectrum 
after elution, and estimated yields, are shown in Fig. 52 and Table 26. The line at 511 keV 
was still visible, but note the lack of peaks at 203 keV and 245 keV, indicating that they 
were not distilled. However, a peak at 976 keV became visible after the distillation 
process. The origin of the 967 keV peak was unclear, as was the 511 keV peak. However, 
using an assumed yield of 1.8 for the 511 keV peak (e.g. 18F = 1.90, 22Na = 1.81,               
68Ga = 1.78), an estimated activity approximately four orders of magnitude less than the 
product 211At. 
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Figure 51. Count rate and furnace temperature data are shown for Experiment 5 during 
distillation. Cold trap coils were removed from the ice bath at 55 minutes. 
 
 
 
Figure 52. The gamma spectrum is shown for the sample of Experiment 5 after elution. 
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Table 26. Estimated yields are shown after distillation for the Experiment 5 sample. 
Radionuclide 
Eγ 
 
(keV) 
Net Peak 
Area 
(Counts) 
Net Peak 
Uncertainty 
 (%) 
Activity 
 
(MBq) 
Activity 
 
(mCi) 
211At 687.0 14600 1.11 817.9 ± 9.1 22.10 ± 0.24 
211Po 
569.7 20900 0.89 490.1 ± 4.4 13.25 ± 0.12 
897.8 14500 0.96 452.6 ± 4.4 12.23 ± 0.12 
Median 211At/211Po 490.1 ± 10.9 13.25 ± 0.30 
210At 245.3 -- -- -- -- 
Unknown 511.1 676 12.41 0.038 ± 0.005 0.001 ± 0.00009 
Unknown 976.6 234 8.40 -- -- 
RCP 211At/211Po (%) 99.992 ± 3.157 
RCY 211At/211Po (%) 62.00 ± 3.08 
 
 
 
3.6 Summary of Production Results 
 
These five experiments satisfactorily produced 211At with yields ranging between 
10.73 – 39.17 MBq µAp-1 h-1, consistent with published yields, at maximum beam 
intensities on the order of  6-7 µAp. Recovered yields were on the order of 20 mCi per 
production run after initial development (median 22.09 mCi ± 0.77). No contamination by 
210At or 210Po was detected.  However, the impurity 135I was detected, as was 22Na and 
possibly another positron emitter. Na-22 was successfully removed during distillation, and 
the remaining 135I was present in the final product at levels much less than 0.005 kBq 
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MBq-1 (μCi mCi-1). The initial experiment, Experiment 1, was used as a proof of 
production. Production runs 2-5 followed the full distillation procedures, and were 
recovered for RCP and RCY analysis. Results are summarized below in Table 27. 
 
Table 27. Yields and purity results are summarized for all production runs. 
Exp. Yield EOB Activity EOB RCY RCP 
 (MBq μAp-1 h-1) (MBq) (mCi) (%) (%) 
1 -- -- -- -- -- 
2 10.7 ± 0.101 011.71 ± 3.4 00.316 ± 0.09 21.13 ± 29.05  99.999 ± 6.036 
3 39.2 ± 0.103 817.5 ± 80.2 22.09 ± 2.17 55.79 ± 17.68 99.964 ± 2.672 
4 29.0 ± 0.100 847.6 ± 35.4 22.91 ± 0.96 50.63 ± 1.17 99.980 ± 0.024 
5 26.0 ± 0.102 790.5 ± 21.8 21.36 ± 0.59 62.00 ± 3.08 99.992 ± 3.157 
 
 
3.7 Radioactive Nanoparticles 
  
Astatine from the final experiment was incorporated into colloidal gold 
nanoparticles. After recovery from the capillary with 38.8 mM sodium tricitrate solution, 
an aliquot of 35 μCi (approximately 100 μL after decay) was prepared. This solution was 
added in the nanoparticle formation process as described before, following the standard 
procedure, albeit scaled to 10 mL total volume. Following production, the nanoparticles 
were centrifuged at 11,540 G for 10 minutes. The supernatant was removed, and the 
nanoparticles were re-suspended and washed with fresh sodium citrate. The sample was 
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spun again, and the nanoparticles were re-suspended in 100 μL of sodium citrate. The 
supernatant and the samples were measured using the dose calibrator, and showed 28 µCi 
(~80% ) retention of activity in the nanoparticles. This established that the colloidal gold 
nanoparticles were successfully formed with radioactive 211At strongly encapsulated 
within the nanoparticles. The final solution was placed in a cuvette and diluted to a volume 
of 1 ml. Using UV-Vis, the wavelength and absorbance peak were measured to assess the 
nominal nanoparticle size and concentration. The measured wavelength was 525 nm with 
an absorbance peak of 0.8 (a.u.).  The nominal nanoparticle diameter was estimated at 
35.1 nm, consistent with preliminary results with non-radioactive nanoparticles. The 
estimated extinction coefficient was 8.45×109 M cm-1. Based on the Beer-Lambert 
equation, the resulting nanoparticle concentration was estimated at 5.7×1010 cm-3.  The 
total number of radioactive atoms in the nanoparticles was 3.88×1010 cm-3, which 
corresponds to a nominal µ of 1.47. The resulting distribution of radioactive atoms per 
nanoparticle is given in Fig. 53. The present strategy of encapsulating radioactive atoms 
in nanoparticles will allow for further functionalization of the nanoparticle corona with 
biologically active molecules, such as mAbs and positron emitting radionuclides for 
further detection as shown in Fig. 54, and as described previously using the anti-HER2 
MAb.  
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Figure 53. Distribution of radioactive atoms per nanoparticle based on a nominal mean of 
µ = 1.47. The fraction of nanoparticles with no radioactive atoms was 0.23, and the 
fraction with one or more radioactive atoms was 0.77. 
 
 
 
 
Figure 54. Sketch showing the strategy for encapsulating radioactive atoms of 211At and 
further functionalizing the nanoparticles using a monoclonal antibody. 
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4. DISCUSSION AND FUTURE WORK 
 
The production experiments presented herein highlight the ability to consistently 
produce 211At at levels acceptable for preclinical research utilizing a research cyclotron. 
Experiments 1 and 2 were proof of concept trials of the new target and distillation 
apparatus. Experiment 1 showed that passive cooling is not an option, with negligible 
ability to produce 211At under these conditions. Experiment 2 included use of the water 
chiller and allowed for significant production. However, the radiochemistry lab set up and 
preparation, distillation process, and general procedures left much to be desired. Several 
small changes were made to the room preparation and process flow to expedite handling 
of the target in Experiment 3. Experiments 3-5 showed marked improvements in yield and 
total recovered product. 
Radionuclidic purity was sufficiently pure in Experiments 3-5 for preclinical trials. 
Official guidelines are not in place for 211At radionuclidic purity in clinical use, but 
expected values can be compared to other radionuclides. For example, pertechnetate must 
meet 1.5×10-4 mCi of 99Mo per mCi of 99mTc (U.S. Pharmacopeia 2005). In our case, 
Experiment 5 meets this requirement at 7.5×10-5, while Experiments 3 and 4 ranged from 
1.9 – 3.6×10-4. This level of purity may prove to be adequate. Understanding the source 
of the iodine impurity and removing it from future production runs will be key to 
increasing radionuclidic purity, as no other contaminants, including 210At or 210Po, were 
detected in the final solutions. As 135I was not reported in any of the literature, the most 
likely source is from the thermal conduction grease used on the target backing. Removing 
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this grease from future experiments will reduce the maximum beam current on target; 
however, with the water chiller in place, the expected decrease in allowable current should 
be negligible, on the order of 5-6 μAe. Further developments in target preparation, 
primarily in reducing the thickness of the bismuth layer to less than 30 μm, will allow the 
Bragg peak to be centered in the aluminum backing plate, allowing for higher currents. It 
was impossible to confirm the identity of the 135I by measuring its daughter 135Xe. This is 
due to the constant removal of air from the fume hood and hot cell where the target was 
stored, as well as the air turnover rate in the radiochemistry room. The relatively long half-
life (9.14 h) of 135Xe means it was likely exhausted prior to decay. Decays that did occur 
near the detector were not quantifiable due to the low decay rate, relatively low gamma-
emission rate (see Appendix A), and inconsistent geometry due to the dispersion of the 
gas. The inert nature of the noble gas ensured that it was not captured in the effluent air 
monitors or charcoal exhaust filters. The distillation apparatus and vessels were 
continuously vented through the charcoal filter and flushed with the argon gas flow. The 
boiling point of xenon (-108.1 °C) is below the temperature of the cold trap, so no impurity 
135Xe was captured during the distillation process. 
Developed targetry and recovery apparatus have proven satisfactory as the basis 
for routine production development. However, to realize routine production able to meet 
consistent research demand, several improvements and considerations must be taken into 
account. Key elements are automation and modularization of components, adapting the 
apparatus to current widespread cyclotron infrastructure, assessing cost reduction 
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methods, furthering long-term preclinical in vivo studies to assess late radiotoxicity 
effects, and standardization of delivery methods. 
Several attempts have been made to facilitate automation and routine production 
capabilities using 211At. Use of premade components to shorten handling time is a 
development goal, as they could be sold and used in kit-like form. Commercial biomedical 
cyclotron facilities utilize kit-based components for the large-scale manufacture of 
radiopharmaceuticals, such as 18FDG (Martin and Akabani 2012). Long-term storage of 
Anti-HER2 (Anti-CD340) tin-based immunoconjugates has been shown to be stable in 
Phosphate Buffered Saline (PBS) at pH>7 and 4 °C for greater than 3 months (Aneheim 
et al. 2015c). Similarly, development of kit based 211At-MABG, the astatine analog to 
MIBG, has been favorable at clinical studies scales (Vaidyanathan et al. 2007). This would 
be ideal for long distance shipping, and for reliable and repeatable radiochemistry at newly 
established facilities. 
A necessary development is the inclusion of automatic synthesis instead of manual 
manipulation. Automated controls, which can be run by dedicated computer software, are 
fundamental to routine use within a hot cell. While it is helpful to have a flexible laboratory 
during preclinical investigations, where concentrations and methods can be optimized for 
the task at hand, routine production and FDA approvals mandate reproducible and 
consistent methods. An essential part of this quality control step is the minimization of 
human interaction. However, automation is not without its own problems. Miniaturization 
of equipment, and the associated reduction in volume of components and feedstock, can 
lead to large percentage errors and significant loss in dead volumes, such as the capillary 
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cold trap coils and valves. Automation has been partially developed for tin-based 
immunoconjugates, but more work is needed. An estimate of 100 μL minimum volumes 
are needed to minimize variation to an acceptable level, but these amounts still result in 
approximately 10% deviations (Anaheim et al. 2015c). 
An example of a preliminary distillation and recovery apparatus utilizing standard 
modular and microfluidic components is shown in Fig. 55 (Anaheim 2015a). In this figure, 
the various components are given as: a) tube furnace; b) quartz crucible; c,d) 3-way 
automated valves; e) cold trap; f) reaction vial for radiolabeling; g) bubbler and charcoal 
traps; h) vacuum pump; i,j) reactants; k) size-exclusion column and PIN diode detector; l) 
syringe loader; m) end-product. This unit has been developed by Anaheim, part of the 
Lindegren group at Gothenburg University in Sweden. This is the latest development by 
this group, which has been one of the leaders in investigating 211At production and 
recovery since the early 2000’s. Use of this automated apparatus has resulted in distillation 
yields from 87-92% using a mixture of methanol and NIS, with labeling yields of N-
succinimidyl 3-(trimethylstannyl)benzoate (m-MeATE) immunoconjugates on the order 
of 75% with excellent RCP (Anaheim et al. 2015a, 2015c). 
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Figure 55. A semi-automated and modular system for distillation and synthesis of 211At 
to m-MeATE-conjugates. See text for explanation of individual components. 
 
 
 The apparatus in Fig. 55 is contained within a glove box, and is similar in size to 
the apparatus used in these experiments (c.f. Fig. 16). The tube furnace is by far the 
bulkiest item in both setups. By implementing an induction furnace, it is expected to 
reduce the overall size of the distillation apparatus such that is can fit in a standardized hot 
cell module enclosure. An example of a commercially available miniature induction 
furnace is shown in Fig. 56. A device similar to this could be adapted to astatine production 
by changing the geometry of the induction coils to contain the quartz crucible. The power 
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supply and controller could be conveniently located outside of the hot cell. Induction 
furnaces provide several advantages in addition to size: heating time is greatly reduced, 
and temperature can be easily controlled using a PLC controller to adjust current. This 
means the control system can be integrated, without having to drive proprietary 
components, as is the case with the Carbolite tube furnace. Heating requires that the 
aluminum target backing plate remains attached to the target; however, this is not an issue 
as the final target design was firmly fixed to the backing plate.  
 
 
 
Figure 56. A commercially available miniature induction furnace. The coil is capable of 
inducing temperatures more than 1100 °C. The power supply and controller may be 
remotely mounted. 
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A simplified method for producing 211At in methanol and sodium citrate solution 
has been examined. Automating the process to produce no-carrier-added 211At in a 
common buffer solution will provide the radionuclide in a form compatible with almost 
all standard immunoconjugation applications (Dadachova 2010, Cederkrantz et al. 2015). 
The standardized product could then be tailored to study-specific needs. A schematic of 
the proposed method is given in Fig. 57. 
 
 
 
Figure 57. A schematic of a modularized and automated 211At distillation apparatus. 
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Standard components utilizing PEEK capillary tubing and Upchurch microfluidic 
connectors (IDEX Health and Science LLC, 619 Oak Harbor, WA 98277) will make the 
module compatible with pre-existing cyclotron facility components. Laboratory supplied 
inert gas, usually helium, is used both to entrain the volatilized 211At, as well as to operate 
the pneumatic valves and syringe pumps. An example of a similar module, in use to 
synthesize 18FDG, is shown in Fig. 58 (ABX GmbH, Heinrich-Glaeser-Strasse 10-14, D-
0454, Germany). This shows an example of what the completed module would look like. 
Automation and control will be provided by the industry standard LabVIEW control 
software (National Instruments, 11500 N. Mopac Expwy, TX 78759). 
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Figure 58. An example of a production module, showing pneumatically controlled syringe 
pumps and valves (ABX, Germany). 
 
Introduction of targetry compatible with automated methods is of additional 
importance. Remote loading and unloading of targets required for reducing operator dose 
in high-yield routine batches. While dose rate from the product 211At is relatively low, 
activated equipment and target backing aluminum (28Al) will have high dose rates, 
especially for batches with hundreds of mCi end-product. In the routine production 
scenario, it is impractical and uneconomical to wait for these activation products to decay; 
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furthermore, routine daily production would cumulatively expose workers beyond 
ALARA considerations. Remote target unloading is therefore essential. One such target is 
the NIRTA solid target solid system from IBA (IBA USA, 2000 Edmund Halley Drive 
Ste. 210, VA 20191). This target has been purchased for future development, and is shown 
in Fig. 59. 
The NIRTA target features remote loading and unloading of target disks, and 
extensive active cooling through chilled water on the rear of the target, and helium cooling 
on the front face of the target. The solid target version of the NIRTA system was developed 
for high activity production of 64Cu and 62Zn/62Cu, and is more than capable of tolerating 
routine heat loads for 211At production, provided the bismuth target layer is sufficiently 
thin. Due to these features, the target is held perpendicularly to the incident beam. While 
this does not allow for spreading the beam out on target, it does allow a for an optimal 
target thickness of approximately 30 μm, as opposed to ~ 5 μm for the angled target. In 
collaboration with material science specialist in the Mechanical Engineering department, 
it is expected that these target thicknesses can be produced uniformly using pulsed laser 
deposition (PLD) or conventional sputtering and physical vapor deposition (PVD) 
techniques. Uniformity of thickness and reproducibility will be required to reliably 
maintain routine production. 
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Figure 59. The NIRTA solid target system is shown. In this view, the beam enters from 
the top right, through the center of the circular flange. 
 
 
An additional purpose of future work is to assess the cost of production. In 2011, 
estimated cost of high-level production at an established facility was on the order of $50-
60 per mCi of 211At, contrasted with approximately $70 per mCi of 123I (Zalutsky and 
Pruszynski 2011). However, the cost of facility set up is very prohibitive, as well as for a 
cyclotron capable of using alpha particle beams. What is not considered is the wide 
availability of cyclotrons capable of producing 123I in current usage via the common p or 
d beams on tellurium targets. While considerable finances are available for medical 
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research and administration, 211At based targeted therapy must be shown to be 
significantly more effective, and/or comparable in costs, or no market for it will develop. 
 In addition to automation, more long-term studies are needed for effects of 211At 
in vivo. While the effectiveness of targeted therapies using 211At is well known, toxicity 
and long-term effects in the body are poorly quantified (McLendon et al 1999, Akabani et 
al. 2006). The FDA put out requirements in 2011 requiring extensive long-term study of 
late radiotoxicity of therapeutic radiopharmaceuticals prior to approval for use in humans 
(U.S. FDA 2011). For example of the importance of this, the long-term effects of anti-
tenascin (anti-81C6) labeled 211At as an endoradiotherapeutic agent for the treatment of 
brain tumors has been investigated. Long term radiotoxicity is present, with an LD10 of 
approximately half that found for 211At in astatide form. However, toxic effects are not 
seen except in the highest animal doses, approaching 100 kBq g-1. This would provide an 
initial upper limit of doses for human tests (McLendon et al. 1999). 
 Other promising future studies include development using immunoconjugation 
techniques coupled with colloidal gold-based nanoparticles. Colloidal gold nanoparticles 
with incorporated 211At would provide an interesting, and potentially very effective, route 
of treatment for several types of tumors, especially hepatocellular carcinoma and renal 
cancers (Wilbur et al. 1993, Paciotti et al. 2006). This is especially promising for 
NHS/EDC coupling to antibodies for increased efficacy in targeting (Bartczak and 
Kanaras 2011). Gold nanoparticles also have the benefit of being easily imaged using MR 
or CT. Alternatively, diagnostic radionuclides, such as 124I, may be incorporated as well, 
allowing for a hybrid diagnostic and therapeutic approach. PET image reconstruction of 
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the therapeutic distribution within the body would make for accurate dose estimates 
without the need to sacrifice the subject to harvest individual organs or perform 
autoradiography. The benefit in human research for such a use is obvious. We have 
previously investigated these methods utilizing radioiodine as astatine analogs (Clanton 
and Akabani, 2017). Preliminary research has been completed using the 211At produced in 
these experiments, as discussed in the results section. Future development of this method, 
including higher specific activity per nanoparticle, protein labelling, and in vitro 
experiments will be forthcoming following future 211At production experiments. 
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 5. CONCLUSION 
 
An inclined external solid target was developed capable of undergoing extended 
(8+ h) irradiations of 29 MeV (7.25 MeV u-1) alpha particles at currents up to 7 μAe. A 
dry distillation apparatus and process was developed to recover the astatine while negating 
radiochemical contamination from target byproduct materials. Several production 
irradiations were performed with favorable results. Production yields ranged between 
10.73 – 39.17 MBq µAp-1 h-1 (0.290 – 1.058 mCi µAp-1 h-1), consistent with published 
yields, at average beam intensities on the order of 5-10 times that used in previous 
experiments (2-3 µAp). Recovered yields were on the order of 740 MBq (20 mCi) per 
production run after initial development (median 22.09 mCi ± 0.77). No contamination by 
210At or 210Po was detected in any of the final products. Trace amounts of 135I were present 
in some instances, with maximum amounts of < 0.04% final yield. 
Overall, production utilizing these methods has proven feasible for small-scale 
studies utilizing 1-20 mCi per experiment. Development of further process automation 
and miniaturization, as well as quality assurance and control protocols, will be required 
for forthcoming standardized production.  
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APPENDIX A 
DECAY DATA FOR SELECTED RADIONUCLIDES 
 
 Decay data and spectra are provided on the following pages for selected 
radionuclides. These data were generated by the code Nuclei, utilizing current (2017) 
Evaluated Nuclear Structure Data Files (ENSDF) (Nagl et al. 2013). These are provided 
to show gamma and x-ray emissions in a convenient format. Spectra are shown as 
arbitrary units of intensity as a function of photon energy.The presented radionuclides 
are listed below, with data on the following pages. 
 
211At and Daughters 
1. 211At207Bi 
2. 211At211Po 
3. 207Bi207Pb 
4. 211Po207Pb 
 
210At and Daughters 
5. 210At206Bi 
6. 210At210Po 
7. 206Bi206Pb 
8. 210Po206Pb 
 
Background Radionuclides and Impurities 
9. 40K40Ar/40Ca 
10. 22Na22Ne 
11. 135I135Xe 
 
Calibration Radionuclides 
12. 137Cs137Ba 
13. 133Ba133Cs 
14. 152Eu152Sm 
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1. 211At207Bi 
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2. 211At211Po 
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3. 207Bi207Pb 
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4. 211Po207Pb 
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5. 210At206Bi 
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6. 210At210Po 
 
 
 
 
 198 
 
7. 206Bi206Pb 
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8. 210Po206Pb 
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9. 40K40Ar/40Ca 
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10. 22Na22Ne 
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11. 135I135Xe 
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12. 137Cs137Ba 
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13. 133Ba133Cs 
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14. 152Eu152Sm 
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APPENDIX B 
TALYS SIMULATION 
 
The nuclear reaction code TALYS was used to simulate production yields and 
reaction channels for 26 MeV alpha particles incident on a pure 209Bi thick target. A 
summary of results was presented in Section 2.2.3, Theoretical Yield. More detailed 
information is provided below. Figure B1 shows the number of nuclei of each reaction 
channel, normalized to 211At, for a 4 h irradiation. Figure B2 shows the relative activity of 
all radioactive products for the same conditions. Selected portions of the TALYS input 
and output file is given following the figures. 
 
 
Number of impurity nuclei, normalized to 211At nuclei, during a 4 h bombardment. 
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Relative product and impurity activity during a 4 h bombardment. 
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TALYS-1.8 (Version: December 28, 2015) 
 
 Copyright (C) 2015  A.J. Koning, S. Hilaire and S. Goriely       
                         NRG          CEA          ULB     
 
 Dimensions - Cross sections: mb, Energies: MeV, Angles: degrees 
 
 ########## USER INPUT ########## 
 
 USER INPUT FILE 
 
 #                                                                                
 # general                                                                        
 #                                                                                
 projectile a                                                                     
 element bi                                                                       
 mass 209                                                                         
 energy 1 30 0.5                                                                  
 area 1                                                                           
 rho 9.8                                                                          
 #                                                                                
 # spherical model                                                                
 #                                                                                
 spherical y                                                                      
 #                                                                                
 # medical isotope production                                                     
 #                                                                                
 production y                                                                     
 ibeam 1                                                                          
 ebeam 28.0                                                                       
 eback 5.0                                                                        
 radiounit mbq: megabecquerel                                                     
 tcool 0.1 d                                                                      
 tirrad 4 h                                                                       
 
 USER INPUT FILE + DEFAULTS 
 
 Keyword           Value   Variable     Explanation 
 
 # 
 # Four main keywords 
 # 
 projectile          a     ptype0       type of incident particle 
 element            Bi     Starget      symbol of target nucleus 
 mass              209     mass         mass number of target 
nucleus 
 energy                    energyfile   file with incident energies 
 # 
 # Basic physical and numerical parameters 
 # 
 ejectiles g n p d t h a   outtype      outgoing particles 
 209 
 
 maxz               12     maxZ         maximal number of protons 
away from the initial compound nucleus 
 maxn               32     maxN         maximal number of neutrons 
away from the initial compound nucleus 
 bins               40     nbins        number of continuum 
excitation energy bins 
 equidistant         n     flagequi     flag to use equidistant 
excitation bins instead of logarithmic bins 
 popmev              n     flagpopmev   flag to use initial 
population per MeV instead of histograms 
 segment             1     segment      number of segments to 
divide emission energy grid 
 maxlevelstar       30     nlevmax      maximum number of included 
discrete levels for target 
 maxlevelsres       10     nlevmaxres   maximum number of included 
discrete levels for residual nucleus 
 maxlevelsbin g     10     nlevbin      maximum number of included 
discrete levels for gamma    channel 
 maxlevelsbin n     10     nlevbin      maximum number of included 
discrete levels for neutron  channel 
 maxlevelsbin p     10     nlevbin      maximum number of included 
discrete levels for proton   channel 
 maxlevelsbin d      5     nlevbin      maximum number of included 
discrete levels for deuteron channel 
 maxlevelsbin t      5     nlevbin      maximum number of included 
discrete levels for triton   channel 
 maxlevelsbin h      5     nlevbin      maximum number of included 
discrete levels for helium-3 channel 
 maxlevelsbin a     30     nlevbin      maximum number of included 
discrete levels for alpha    channel 
 ltarget             0     ltarget      excited level of target 
 isomer           1.00E+00 isomer       definition of isomer in 
seconds 
 transpower          5     transpower   power for transmission 
coefficient limit 
 transeps         1.00E-08 transeps     limit for transmission 
coefficient 
 xseps            1.00E-07 xseps        limit for cross sections 
 popeps           1.00E-03 popeps       limit for population cross 
section per nucleus 
 Rfiseps          1.00E-03 Rfiseps      ratio for limit for fission 
cross section per nucleus 
 elow             1.00E-06 elow         minimal incident energy for 
nuclear model calculations 
 angles             90     nangle       number of angles 
 anglescont         18     nanglecont   number of angles for 
continuum 
 anglesrec           1     nanglerec    number of recoil angles 
 maxenrec           20     maxenrec     number of recoil energies 
 channels            n     flagchannels flag for exclusive channels 
calculation 
 210 
 
 maxchannel          4     maxchannel   maximal number of outgoing 
particles in individual channel description 
 micro               n     flagmicro    flag for completely 
microscopic Talys calculation 
 best                n     flagbest     flag to use best set of 
adjusted parameters 
 bestbranch          y     flagbestbr   flag to use flag to use 
only best set of branching ratios 
 bestend             n     flagbestend  flag to put best set of 
parameters at end of input file 
 relativistic        y     flagrel      flag for relativistic 
kinematics 
 recoil              n     flagrecoil   flag for calculation of 
recoils 
 labddx              n     flaglabddx   flag for calculation of DDX 
in LAB system 
 recoilaverage       n     flagrecoilav flag for average velocity 
in recoil calculation 
 channelenergy       n     flagEchannel flag for channel energy for 
emission spectrum 
 reaction            y     flagreaction flag for calculation of 
nuclear reactions 
 astro               n     flagastro    flag for calculation of 
astrophysics reaction rate 
 astrogs             n     flagastrogs  flag for calculation of 
astrophysics reaction rate with target in ground state only 
 massmodel           2     massmodel    model for theoretical 
nuclear mass 
 expmass             y     flagexpmass  flag for using experimental 
nuclear mass if available 
 disctable           1     disctable    table with discrete levels 
 production          y     flagprod     flag for isotope production 
 outfy               n     flagoutfy    flag for output detailed 
fission yield calculation 
 gefran          50000     gefran       number of random events for 
GEF calculation 
 Estop            1000.000 Estop        incident energy above which 
TALYS stops 
 rpevap              n     flagrpevap   flag for evaporation of 
residual products at high incident energies 
 maxZrp             12     maxZrp       maximal number of protons 
away from the initial compound nucleus before residual evaporation 
 maxNrp             32     maxNrp       maximal number of neutons 
away from the initial compound nucleus before residual evaporation 
 # 
 # Isotope production  
 # 
 Ebeam              28.000 beam         incident energy in MeV for 
isotope production 
 Eback               5.000 Eback        lower end of energy range 
in MeV for isotope  production 
 211 
 
 radiounit             mbq radiounit    unit for radioactivity 
 yieldunit             num yieldunit    unit for isotope yield 
 Ibeam               1.000 Ibeam        beam current in mA 
 Tirrad              4     Tirrad       h of irradiation time 
 Area                1.000 Area         target area in cm^2 
 rho                 9.800 rhotarget    target density [g/cm^3]  
 # 
 
 
....... 
 
Production of Z= 85 A=211 (211At) - Total 
 
 Q-value    = -20.329056 
 E-threshold=  20.718418 
 
 Energy   Cross section 
 
  1.00000E+00 0.00000E+00                                                         
  1.50000E+00 0.00000E+00                                                         
  2.00000E+00 0.00000E+00                                                         
  2.50000E+00 0.00000E+00                                                         
  3.00000E+00 0.00000E+00                                                         
  3.50000E+00 0.00000E+00                                                         
  4.00000E+00 0.00000E+00                                                         
  4.50000E+00 0.00000E+00                                                         
  5.00000E+00 0.00000E+00                                                         
  5.50000E+00 0.00000E+00                                                         
  6.00000E+00 0.00000E+00                                                         
  6.50000E+00 0.00000E+00                                                         
  7.00000E+00 0.00000E+00                                                         
  7.50000E+00 0.00000E+00                                                         
  8.00000E+00 0.00000E+00                                                         
  8.50000E+00 0.00000E+00                                                         
  9.00000E+00 0.00000E+00                                                         
  9.50000E+00 0.00000E+00                                                         
  1.00000E+01 0.00000E+00                                                         
  1.05000E+01 0.00000E+00                                                         
  1.10000E+01 0.00000E+00                                                         
  1.15000E+01 0.00000E+00                                                         
  1.20000E+01 0.00000E+00                                                         
  1.25000E+01 0.00000E+00                                                         
  1.30000E+01 0.00000E+00                                                         
  1.35000E+01 0.00000E+00                                                         
  1.40000E+01 0.00000E+00                                                         
  1.45000E+01 0.00000E+00                                                         
  1.50000E+01 0.00000E+00                                                         
  1.55000E+01 0.00000E+00                                                         
  1.60000E+01 0.00000E+00                                                         
  1.65000E+01 0.00000E+00                                                         
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  1.70000E+01 0.00000E+00                                                         
  1.75000E+01 0.00000E+00                                                         
  1.80000E+01 0.00000E+00                                                         
  1.85000E+01 0.00000E+00                                                         
  1.90000E+01 0.00000E+00                                                         
  1.95000E+01 0.00000E+00                                                         
  2.00000E+01 0.00000E+00                                                         
  2.05000E+01 0.00000E+00                                                         
  2.10000E+01 3.48345E+00                                                         
  2.15000E+01 2.93709E+01                                                         
  2.20000E+01 6.53661E+01                                                         
  2.25000E+01 1.20925E+02                                                         
  2.30000E+01 1.89442E+02                                                         
  2.35000E+01 2.62839E+02                                                         
  2.40000E+01 3.37422E+02                                                         
  2.45000E+01 4.09195E+02                                                         
  2.50000E+01 4.74891E+02                                                         
  2.55000E+01 5.34939E+02                                                         
  2.60000E+01 5.92596E+02                                                         
  2.65000E+01 6.46036E+02                                                         
  2.70000E+01 6.95778E+02                                                         
  2.75000E+01 7.41376E+02                                                         
  2.80000E+01 7.84275E+02                                                         
  2.85000E+01 8.19960E+02                                                         
  2.90000E+01 8.48885E+02                                                         
  2.95000E+01 8.47699E+02                                                         
  3.00000E+01 8.29451E+02        
 
 
...... 
 
 
 
Summary of isotope production  
 
 Maximal irradiation time    :   0 years   0 days   4 hours   0 
minutes   0 seconds  
 Cooling time                :   0 years   0 days   0 hours   0 
minutes   0 seconds  
 Energy range                :  28.000 -->   5.000 MeV 
 Beam current                :        1.000 mA 
 Target material density     :        9.800 g/cm^3 
 Target area                 :        1.000 cm^2 
 Effective target thickness  :        0.018 cm 
 Effective target volume     :        0.018 cm^3 
 Effective target mass       :        0.174 g    
 Number of target atoms      :  5.01017E+20 
 Number of incident particles:  3.12075E+15 s^-1 
 Produced heat in target     :       23.000 kW 
 
 Execution time:  0 hours  1 minutes  3.10 seconds  
